{ "totalSites": 16, "totalPages": 113, "sites": [ { "id": "1-pct-treaty-impact", "type": "book", "title": "The 1% Treaty: Harnessing Greed to Eradicate Disease", "description": "6.65 thousand diseases have zero FDA-approved treatments; at current trial capacity, exploring them takes ~443 years. Redirecting 1% of military spending scales capacity 12.3x, cutting the timeline to ~36 years and preventing 10.7 billion deaths. At $0.00177/DALY, 50.3kx more cost-effective than the best existing interventions. Incentive Alignment Bonds make adoption politically viable.", "abstract": "6.65 thousand diseases have 0 FDA-approved treatments. At current trial capacity (15 diseases/year), exploring the therapeutic search space takes ~443 years. Redirect 1% of military spending ($27.2B/year) to pragmatic clinical trials. Trial capacity jumps 12.3x. Search space explored in ~36 years instead of centuries. Average treatment reaches patients 212 years sooner. Timeline shift saves 10.7 billion deaths, valued at $84.8 quadrillion. Cost-effectiveness: $0.00177/DALY, 50.3kx better than bed nets. Even at 1% probability of treaty adoption, risk-adjusted cost-effectiveness remains superior to the best existing global health interventions. Incentive Alignment Bonds address political feasibility by tying legislators' career incentives to a public voting scorecard.", "siteUrl": "https://impact.warondisease.org", "favicon": "https://impact.warondisease.org/assets/icons/economics-favicon.png", "ogImage": "https://impact.warondisease.org/assets/og/economics-og-1200x630.jpg", "pdfUrl": "https://impact.warondisease.org/1-percent-treaty-impact.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18161560", "version": "1.0.0", "edition": "First Edition", "copyright": "© 2025 The Institute for Accelerated Medicine", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Public Health, Medical Research, Peace Economics, Health Economics, Policy Reform", "category": "Non-fiction, Public Policy, Health Economics, Peace Studies", "keywords": [ "war-on-disease", "1-percent-treaty", "medical-research", "public-health", "peace-dividend", "decentralized-trials", "dfda", "dih", "victory-bonds", "health-economics", "cost-benefit-analysis", "clinical-trials", "drug-development", "regulatory-reform", "military-spending", "peace-economics", "decentralized-governance", "wishocracy", "blockchain-governance", "impact-investing" ], "audience": "Policy Makers, Investors, Healthcare Professionals, Researchers", "format": "Website", "genre": "Public Policy, Health Economics, Peace Studies", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "8cb62a4c-0a10-4a92-a9ab-088c5b2cf094", "cname": "impact-warondisease-org.netlify.app" }, "indexSource": "knowledge/economics/1-pct-treaty-impact.qmd", "outputDir": "_site/1-pct-treaty-impact", "publishing": { "ownSite": { "url": "https://impact.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522796", "doi": "10.5281/zenodo.18161560" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Health Affairs", "tier": 1, "status": "target", "url": "" }, { "name": "Value in Health", "tier": 2, "status": "target", "url": "" }, { "name": "The Lancet", "tier": 1, "status": "target", "type": "commentary" } ] }, "pages": [ { "path": "knowledge/economics/1-pct-treaty-impact.qmd", "url": "https://impact.warondisease.org/economics/1-pct-treaty-impact.html", "title": "The 1% Treaty: Harnessing Greed to Eradicate Disease", "description": "6.65 thousand diseases have zero FDA-approved treatments; at current trial capacity, exploring them takes ~443 years. Redirecting 1% of military spending scales capacity 12.3x, cutting the timeline to ~36 years and preventing 10.7 billion deaths. At $0.00177/DALY, 50.3kx more cost-effective than the best existing interventions. Incentive Alignment Bonds make adoption politically viable.", "image": "https://impact.warondisease.org/assets/og-images/knowledge/economics/economics-og-retro-academic.jpg", "tags": [ "economics", "cost-benefit-analysis", "public-health", "peace-dividend", "roi", "impact-assessment", "health-economics" ], "sections": [ "Abstract", "Primary Findings", "How Pragmatic Trials Increase Safety", "Introduction", "Historical Precedents for Grand Challenges", "The Medical Research Bottleneck", "Contribution to Literature", "Research Hypothesis", "Nomenclature and Key Terms", "Problem Statement", "Current Resource Allocation", "Mortality and Morbidity Burden", "How It Works", "A Decentralized Framework for Drug Assessment", "Trial Cost Reduction", "Enhanced Safety Monitoring", "Comparative Effectiveness Rankings", "Outcome Labels", "Summary of Results", "Total Economic Value", "Research Acceleration", "Treatment Timeline Acceleration", "Suffering Reduction", "Lives Saved", "DALYs Averted", "Why \"Eventually Avoidable\" Matters", "The Leverage Mechanism: Why 1% Is Enough", "The Peace Dividend (Multiplier Differential)", "Research Efficiency Dividend (Infrastructure Leverage)", "15–40 \"NIH equivalents\" of new research capacity", "How It Increases National Security", "What doesn't change", "What improves", "The De-escalation Trajectory", "Why The Ratchet Works: The Incentive Alignment Bond Scaling Engine", "Treaty Funding Allocation", "Political Economy and Financing", "Incentive Alignment Bonds", "Dominance Analysis", "Quantitative Comparison", "Methodology", "Cost-Benefit Framework", "Cost Components", "Benefit Components", "ROI Calculation", "Combined Annual Benefits Uncertainty", "Cost-Effectiveness Analysis", "Expected Value Under Political Uncertainty", "Policy Advocacy Leverage vs Direct Funding", "Direct Funding Still Excellent", "Detailed NPV Formulas", "Quality-Adjusted Life Year (QALY) Valuation", "QALY Calculation Model", "Economist Verification: Complete Derivation Chains", "Trial Capacity Multiplier Derivation (12.3x)", "Timeline Shift Derivation (212 years)", "DALYs Averted Derivation (565 billion DALYs)", "Cost per DALY Derivation ($0.00177)", "ROI Derivation (Conservative: 637:1)", "ROI Derivation (Complete: 84.8M:1)", "Lives Saved Derivation (10.7 billion deaths)", "Regulatory Delay Elimination Derivation", "Annual Recurring Benefits Derivation", "Verification Summary", "Counterfactual Baseline Specification", "Peace Dividend Calculation Methodology", "Relative Importance", "Economic benefits of reduced military spending", "Research Acceleration Mechanism", "Treatment Discovery Through Therapeutic Space Exploration", "Addressing the Returns Question: Diminishing, Linear, or Compounding?", "Data Sources and Primary Inputs", "Military and Conflict Data", "Sensitivity Analysis Approach", "Key Analytical Assumptions", "Strategic Stability Assumption", "Linear Scaling Assumption", "Adoption Rate Assumptions", "Cost Reduction Assumptions", "Historical Precedent: Pre-1962 Physician-Led Efficacy Trials", "Political Feasibility Assumption", "Expected Value Analysis Accounting for Political Risk", "Time Inconsistency and Commitment Credibility", "Technology Constancy Assumption", "Data Quality and Availability", "Scenario Analysis: Complete Case", "Timeline Shift Value", "Individual-Level Economic Impact", "Who Benefits and How", "Adoption Dynamics: Game-Theoretic Analysis", "Implementation Strategy", "Step 1: Global Mandate (The Philanthropic Catalyst)", "Step 2: Capitalization via Incentive Alignment Bonds (IABs)", "Step 3: Implement the Legislative Strategy", "Step 4: Build the Infrastructure", "Step 5: The Statutory Administration Utility", "Implementation Budget Breakdown", "Detailed Technical References", "Risk Analysis and Mitigation", "The \"But Politicians Won't Do It\" Problem", "Safety Concerns", "Patient Agency and Autonomy", "Accountability measures", "Limitations and Uncertainties", "Adoption Timeline Uncertainty", "Pragmatic Trial Internal Validity and Selection Bias", "QALY Calculation Uncertainties", "Data Limitations", "Generalizability Constraints", "Uncertainty Quantification", "Scenario Analysis Robustness", "General Equilibrium Effects", "Conditional Benefits Interpretation", "Limitations Summary", "Why This Differs from Failed Megaprojects", "Policy Implications", "National Health Budgets", "International Development Priorities", "Military Budget Allocation", "Global Health Funding Mechanisms", "Implementation Pathway", "Bottom Line for Policymakers", "Treaty Adoption: Political Will and Diplomatic Strategy", "Why Simultaneous Commitment Works: Escaping the Prisoner's Dilemma", "Historical Treaty Precedents", "Adoption Pathway", "Conclusion" ], "published": true, "lastmod": "2026-03-06" }, { "path": "knowledge/appendix/economist-feedback-treaty.qmd", "url": "https://impact.warondisease.org/appendix/economist-feedback-treaty.html", "title": "Is This Crazy?", "description": "A 1% redirect of military spending to pragmatic trials claims to avert 565 billion DALYs at $0.00177 each. One-page calculation chain for economist review.", "sections": [ "Why You Should Take 15 Minutes to Validate This Model", "Bottom-Line Claims", "The Treaty Mechanism", "Calculation Chain", "Key Assumptions Requiring Sign-Off", "1. Eventually Avoidable Fraction: 92.6% of disease deaths", "2. Trial Capacity = Discovery Rate (Linear Assumption)", "3. Political Success Probability: 1%", "4. $1B Campaign -> $27.2B/yr Government Funding (Treaty Leverage)", "5. Pragmatic Trial Cost: $929/patient", "Full Materials" ], "published": true, "lastmod": "2026-03-06" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://impact.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/references.qmd", "url": "https://impact.warondisease.org/references.html", "title": "Source Quotes and References", "description": "Every claim in this manual has a receipt. 347 sources, because 'trust me, I'm an alien' is not a citation format your species recognizes.", "image": "https://impact.warondisease.org/assets/og-images/knowledge/references-og-bw-academic.jpg", "tags": [ "references" ], "published": true, "lastmod": "2026-03-03" } ], "pageCount": 4 }, { "id": "cost-of-change", "type": "website", "title": "The Price of Political Change: A Cost-Benefit Framework for Policy Incentivization", "description": "What's the maximum cost to achieve any policy change through legal democratic channels? $25B for the US, $200B globally. For high-value reforms like military-to-health reallocation, this yields ROI exceeding 400,000:1.", "siteUrl": "https://cost-of-change.warondisease.org", "favicon": "https://cost-of-change.warondisease.org/assets/icons/favicon.png", "ogImage": "https://cost-of-change.warondisease.org/assets/og/cost-of-change-og-1200x630.jpg", "pdfUrl": "https://cost-of-change.warondisease.org/cost-of-change-analysis.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18356215", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Political Economy, Campaign Finance, Lobbying, Public Choice, Cost-Benefit Analysis", "category": "Academic Paper, Political Economy, Mechanism Design, Public Policy", "keywords": [ "political-economy", "campaign-finance", "lobbying", "mechanism-design", "public-choice", "cost-benefit-analysis", "political-feasibility", "political-reform", "democracy" ], "audience": "Researchers, Policy Makers, Political Scientists, Economists, Political Reform Advocates", "format": "Working Paper", "genre": "Political Science, Economics, Public Choice, Public Policy", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "7daf95c9-506f-4cb9-99e3-2f0f9477f816", "cname": "cost-of-change-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/cost-of-change-analysis.qmd", "outputDir": "_site/cost-of-change", "publishing": { "ownSite": { "url": "https://cost-of-change.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522030", "doi": "10.5281/zenodo.18356215" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Public Choice", "tier": 2, "status": "target", "url": "" }, { "name": "Journal of Political Economy", "tier": 1, "status": "target", "url": "" }, { "name": "American Economic Review", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/cost-of-change-analysis.qmd", "url": "https://cost-of-change.warondisease.org/appendix/cost-of-change-analysis.html", "title": "The Price of Political Change: A Cost-Benefit Framework for Policy Incentivization", "description": "What's the maximum cost to achieve any policy change through legal democratic channels? $25B for the US, $200B globally. For high-value reforms like military-to-health reallocation, this yields ROI exceeding 400,000:1.", "image": "https://cost-of-change.warondisease.org/assets/og-images/knowledge/appendix/cost-of-change-analysis-og-retro-academic.jpg", "sections": [ "Introduction", "The Political Impossibility Objection", "Political Change as an Investment", "Contribution and Roadmap", "Literature Review", "Theoretical Framework", "The Political Cost Function", "Campaign Finance Component", "Lobbying Component", "Career Value Component", "The Benefit Function", "Breakeven Condition", "Empirical Methodology", "US Political System Cost Estimates", "Global Estimates", "Uncertainty Analysis", "Implications for Major Health Funders", "Current Philanthropic Efficiency", "The Political Reform ROI Calculation", "Who Can Afford What", "ROI Comparison", "Why This Is Rational for Funders", "Case Study: Military-to-Pragmatic Clinical Trial Reallocation (1% Treaty)", "Other Policy Domains", "Limitations", "Conclusion", "References" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://cost-of-change.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "dfda-impact", "type": "website", "title": "Ubiquitous Pragmatic Trial Impact Analysis: How to Prevent a Year of Death and Suffering for 84 Cents", "description": "Only 15 diseases/year get their first treatment each year. With 6.65 thousand diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at $0.842 per year of healthy life saved.", "siteUrl": "https://dfda-impact.warondisease.org", "favicon": "https://dfda-impact.warondisease.org/assets/icons/dfda-favicon.png", "ogImage": "https://dfda-impact.warondisease.org/assets/og/dfda-impact-og-1200x630.jpg", "pdfUrl": "https://dfda-impact.warondisease.org/dfda-impact-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18243914", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 The Institute for Accelerated Medicine", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Health Economics, Cost-Benefit Analysis, ROI, Clinical Trials, Drug Development", "category": "Academic Paper, Health Economics, Policy Analysis", "keywords": [ "dfda", "cost-benefit-analysis", "roi", "return-on-investment", "clinical-trials", "drug-development", "health-economics", "pragmatic-trials", "recovery-trial", "real-world-evidence", "regulatory-efficiency", "decentralized-fda" ], "audience": "Policy Makers, Health Economists, Regulatory Scientists, Investors, Healthcare Administrators", "format": "Working Paper", "genre": "Health Economics, Policy Analysis, Cost-Benefit Analysis", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "a314a33e-3155-4067-8624-706266899419", "cname": "impact-dfda-earth.netlify.app" }, "indexSource": "knowledge/appendix/dfda-impact-paper.qmd", "outputDir": "_site/dfda-impact", "publishing": { "ownSite": { "url": "https://dfda-impact.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522032", "doi": "10.5281/zenodo.18243914" }, { "platform": "medrxiv", "status": "pending", "url": "" }, { "platform": "ssrn", "status": "pending", "url": "" } ], "journals": [ { "name": "Value in Health", "tier": 2, "status": "target", "url": "" }, { "name": "Health Affairs", "tier": 1, "status": "target", "url": "" }, { "name": "PharmacoEconomics", "tier": 2, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/dfda-impact-paper.qmd", "url": "https://dfda-impact.warondisease.org/appendix/dfda-impact-paper.html", "title": "Ubiquitous Pragmatic Trial Impact Analysis: How to Prevent a Year of Death and Suffering for 84 Cents", "description": "Only 15 diseases/year get their first treatment each year. With 6.65 thousand diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at $0.842 per year of healthy life saved.", "image": "https://dfda-impact.warondisease.org/assets/og-images/knowledge/appendix/dfda-impact-paper-og-retro-academic.jpg", "tags": [ "dfda", "roi", "economics", "cost-effectiveness" ], "sections": [ "Executive Summary", "The Receipts", "Why These Numbers Are Large", "Key Metric Derivations", "Interpreting These Figures: Cumulative, Not Annual", "The Discovery Capacity Model", "Capabilities", "Core Model: An Open Coordination Protocol", "Key Capabilities", "Potential Impact on the Status Quo", "Addressing Key Concerns", "Historical Validation: Pre-1962 Physician-Led Efficacy Testing", "Why \"Eventually Avoidable\" Matters", "Trial Funding Scenario", "On the Funding Assumption", "Framework Costs (ROM Estimates)", "Upfront Build Costs (30 Months)", "Ecosystem Participants", "Why This Matters", "Annual Operational Costs (5M MAU Target Scale)", "Scenario Based ROM Estimates for Broader Initiative Costs", "Benefit Analysis - Quantifying the Savings", "Market Size and Impact", "Decentralized Trial Costs Modeled on Pragmatic Trials", "Scope of Cost Reduction", "Overall Savings", "Economic Value of Earlier Access to Treatments", "Gross R&D Savings from a Decentralized FDA", "Post-Safety Efficacy Lag Elimination", "Relative Magnitude", "Safety and Risk Management", "Caution", "ROI Analysis for a Decentralized FDA", "Monte Carlo Distributions", "Research Acceleration Mechanism", "The Unexplored Therapeutic Frontier", "Addressing the Returns Question: Diminishing, Linear, or Compounding?", "Data Sources and Methodological Notes", "Conclusion", "Disclaimer", "Verification: Complete Derivation Chains", "Trial Capacity Multiplier Derivation", "Timeline Shift Derivation", "Lives Saved Derivation", "Cost per DALY Derivation", "ROI Derivation", "Verification Summary", "Key Analytical Assumptions", "Linear Scaling Assumption", "Adoption Rate Assumptions", "Cost Reduction Assumptions", "Eventually Avoidable Mortality Assumption", "Counterfactual Baseline Specification", "Methodology Validation Against Accepted Benchmarks", "Appendix Calculation Frameworks and Detailed Analysis", "Calculation Framework - NPV Methodology", "Financial Analysis Summary", "Cost-Utility Framework", "Comparative Cost-Effectiveness - A Decentralized Framework vs Other Interventions", "Methodology Notes", "Data Limitations", "Comparison to Other Major Public Investments", "Why This Differs from Failed Megaprojects" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://dfda-impact.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/economist-feedback-dfda.qmd", "url": "https://dfda-impact.warondisease.org/appendix/economist-feedback-dfda.html", "title": "Is This Crazy?", "description": "Integrating pragmatic trials into routine healthcare claims to clear a 443 years treatment backlog at $0.842/DALY. One-page calculation chain for economist review.", "sections": [ "Why You Should Take 15 Minutes to Validate This Model", "Bottom-Line Claims", "Calculation Chain", "Key Assumptions Requiring Sign-Off", "1. Eventually Avoidable Fraction: 92.6% of disease deaths", "2. Trial Capacity = Discovery Rate", "3. Pragmatic Trial Cost: $929/patient", "Full Materials" ], "published": true, "lastmod": "2026-02-19" } ], "pageCount": 3 }, { "id": "dfda-spec", "type": "website", "title": "The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials)", "description": "We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.", "siteUrl": "https://dfda-spec.warondisease.org", "favicon": "https://dfda-spec.warondisease.org/assets/icons/dfda-favicon.png", "ogImage": "https://dfda-spec.warondisease.org/assets/og/dfda-spec-og-1200x630.jpg", "pdfUrl": "https://dfda-spec.warondisease.org/dfda-spec-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18203375", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 The Institute for Accelerated Medicine", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Pharmacovigilance, Real-World Evidence, N-of-1 Trials, Causal Inference, Statistical Methods", "category": "Academic Paper, Medical Research, Methodology", "keywords": [ "dfda", "predictor-impact-score", "pharmacovigilance", "real-world-evidence", "n-of-1-trials", "causal-inference", "bradford-hill-criteria", "treatment-effects", "adverse-events", "outcome-labels", "statistical-methods", "dfda", "decentralized-fda" ], "audience": "Researchers, Regulatory Scientists, Biostatisticians, Pharmacoepidemiologists, Health Data Scientists", "format": "Working Paper", "genre": "Biostatistics, Pharmacoepidemiology, Methodology", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "01e9af64-b6d0-48ee-8c3d-43994745ac3f", "cname": "dfda-spec-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/dfda-spec-paper.qmd", "outputDir": "_site/dfda-spec", "publishing": { "ownSite": { "url": "https://dfda-spec.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522034", "doi": "10.5281/zenodo.18203375" }, { "platform": "medrxiv", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "stat.ME" } ], "journals": [ { "name": "Clinical Pharmacology & Therapeutics", "tier": 2, "status": "target", "url": "" }, { "name": "Pharmacoepidemiology and Drug Safety", "tier": 2, "status": "target", "url": "" }, { "name": "Drug Safety", "tier": 2, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/dfda-spec-paper.qmd", "url": "https://dfda-spec.warondisease.org/appendix/dfda-spec-paper.html", "title": "The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials)", "description": "We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.", "image": "https://dfda-spec.warondisease.org/assets/og-images/knowledge/appendix/dfda-spec-paper-og-bw-academic.jpg", "tags": [ "appendix", "working-paper", "methodology", "n-of-1-trials", "real-world-evidence", "pharmacovigilance", "causal-inference", "bradford-hill", "statistical-methods" ], "sections": [ "Abstract", "System Overview: From Methodology to Implementation", "What Patients See", "What Companies See", "Where This Methodology Fits", "Introduction", "The Human Cost of the Current System", "The Pharmacovigilance Gap", "The Real-World Data Opportunity", "Our Contribution", "Data Collection and Integration", "Data Sources", "Variable Ontology", "Measurement Structure", "Unit Standardization", "Mathematical Framework", "Data Structure", "Temporal Alignment", "Pair Generation Strategies", "Filling Value Logic", "Baseline Definition and Outcome Estimation", "Percent Change from Baseline", "Correlation Coefficients", "Z-Score Normalization", "Statistical Significance", "Hyperparameter Optimization", "Population Aggregation", "Individual to Population", "Standard Error and Confidence Intervals", "Heterogeneity Assessment", "Data Quality Requirements", "Minimum Thresholds", "Variance Validation", "Outcome Value Spread", "Predictor Impact Score", "What Makes the Predictor Impact Score Novel", "User-Level Predictor Impact Score", "Aggregate (Population-Level) Predictor Impact Score", "Z-Score and Effect Magnitude Factor", "Temporality Factor", "Percent Change from Baseline", "Statistical Significance", "Interest Factor", "Additional Data Quality Components", "Bradford Hill Criteria Mapping", "Interpreting Predictor Impact Scores", "Provisional Thresholds - Not Yet Validated", "Optimal Daily Value for Precision Dosing", "Saturation Constant Rationale", "Effect Following High vs Low Predictor Values", "Predictor Baseline and Treatment Averages", "Relationship Quality Filters", "Variable Valence", "Temporal Parameter Optimization", "Spearman Rank Correlation", "Outcome Label Generation", "Predictor Analysis Reports", "Report Structure", "Category-Specific Analysis", "Verification Status", "Outcome Labels vs. FDA Drug Labels", "Worked Example: Complete Outcome Label", "Treatment Ranking System", "Within-Category Rankings", "Ranking Algorithm", "Confidence Weighting", "Comparative Effectiveness Display", "Safety and Efficacy Quantification", "Safety Signal Detection", "Efficacy Signal Detection", "Benefit-Risk Assessment", "Addressing the Bradford Hill Criteria", "Complete Criteria Mapping", "Quantitative Criteria Details", "Validation and Quality Assurance", "User Voting System", "Automated Quality Checks", "Flagged Study Handling", "Stage 2: Pragmatic Trial Confirmation", "The Two-Stage Pipeline", "Pragmatic Trial Methodology", "Signal-to-Trial Prioritization", "Comparative Effectiveness Randomization", "Feedback Loop: Trial Results Improve Observational Models", "Output: Validated Outcome Labels", "Limitations and How They're Addressed", "Fundamental Limitations: Observational Stage", "Methodological Weaknesses: Addressed by Two-Stage Design", "Residual Limitations", "What This Framework CAN Now Do", "Implementation Guide", "System Architecture", "Core Algorithm: Pair Generation", "Core Algorithm: Baseline Separation", "Algorithm 3: Predictor Impact Score Calculation", "Reference Implementation", "Regulatory Considerations", "Positioning Relative to RCTs", "Evidence Hierarchy Integration", "FDA Real-World Evidence Framework Alignment", "Validation Framework", "The Critical Question", "Proposed Validation Study", "Known Limitations Requiring Validation", "Future Directions", "Methodological Improvements", "Validation Priorities", "Implementation Enhancements", "Conclusion", "Appendix A: Effect Size Classification", "Appendix B: Variable Category Defaults", "Appendix C: Glossary", "Appendix D: Worked Example", "Example: Calculating Predictor Impact Score for \"Magnesium → Sleep Quality\"", "Appendix E: Analysis Workflow" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://dfda-spec.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "drug-development-cost", "type": "book", "title": "Drug Development Cost Increase Analysis", "description": "Rigorous analysis of the 105x increase in drug development costs from pre-1962 to 2024, using Baily (1972) academic study with CPI adjustments and sensitivity analysis", "abstract": "Drug development costs have increased approximately 105x in real terms since the 1962 Kefauver-Harris Amendment. This analysis uses the Baily (1972) academic study as the primary source, adjusts for inflation via Bureau of Labor Statistics CPI data, and validates the finding against six independent real-world price comparisons: generic vs. brand-name drugs, supplements vs. prescriptions, compounding pharmacies vs. FDA-approved products, veterinary vs. human drugs, orphan drug pricing, and historical antibiotic economics. Monte Carlo sensitivity analysis confirms the estimate is robust across plausible input ranges. The magnitude is consistent with independent estimates of 100-400x from multiple research groups.", "siteUrl": "https://drug-cost.warondisease.org", "favicon": "https://drug-cost.warondisease.org/assets/icons/economics-favicon.png", "ogImage": "", "pdfUrl": "https://drug-cost.warondisease.org/drug-development-cost-analysis.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "version": "1.0.0", "edition": "First Edition", "copyright": "© 2025 The Institute for Accelerated Medicine", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Drug Development, Health Economics, Regulatory Analysis, FDA Policy", "category": "Non-fiction, Health Economics, Regulatory Analysis", "keywords": [ "drug-development-cost", "fda-regulation", "kefauver-harris-amendment", "clinical-trials", "pharmaceutical-economics", "regulatory-burden", "health-economics", "baily-1972", "tufts-csdd", "orphan-drugs" ], "audience": "Policy Makers, Health Economists, Pharmaceutical Researchers, Regulatory Reform Advocates", "format": "Working Paper", "genre": "Health Economics, Regulatory Analysis", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "d739329f-a0cb-44b9-91a1-9921345a75c2", "cname": "drug-cost-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/drug-development-cost-analysis.qmd", "outputDir": "_site/drug-development-cost", "pages": [ { "path": "knowledge/appendix/drug-development-cost-analysis.qmd", "url": "https://drug-cost.warondisease.org/appendix/drug-development-cost-analysis.html", "title": "Drug Development Cost Increase Analysis", "description": "Rigorous analysis of the 105x increase in drug development costs from pre-1962 to 2024, using Baily (1972) academic study with CPI adjustments and sensitivity analysis", "image": "https://drug-cost.warondisease.org/assets/og-images/knowledge/appendix/drug-development-cost-analysis-og-retro-academic.jpg", "sections": [ "The Short Version", "Historical Data Sources", "Pre-1962 Drug Development Costs", "Current Drug Development Costs", "Inflation-Adjusted Calculations", "Primary Method: Baily (1972) Academic Study", "Alternative Method: Congressional Testimony (1977)", "Why Inflation Doesn't Explain This", "Development Timeline Expansion", "Higher Failure Rates", "Trial Complexity", "Preclinical Requirements", "How Solid Is This Number?", "Which Inputs Matter Most", "Full Range of Outcomes", "Input Distributions", "Alternative Scenarios", "Independent Validation", "Sanity Checks: Real-World Price Comparisons", "Generic vs. Brand-Name Drugs (Patent Cliff Evidence)", "Nutritional Supplements vs. Prescription Drugs (Same Molecule, Different Regulation)", "Compounding Pharmacies (Custom Manufacturing Without FDA Approval)", "Veterinary Drugs vs. Human Drugs (Same Molecule, Different Species)", "Orphan Drugs (Full Development Cost Exposure)", "Historical Price Trajectory (Penicillin: 1942 vs. 2024)", "Cross-Validation: All Six Checks Confirm 105x Development Cost Increase", "Addressing Common Objections", "\"That can't be right. It's too high!\"", "\"Doesn't that include marketing costs?\"", "\"What about technological improvements reducing costs?\"", "What This Means", "Fixing This Has Massive ROI", "Pre-1962 System Wasn't Broken", "Real-World Evidence Can Reverse This", "Conclusion", "References", "Technical Parameters" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://drug-cost.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/references.qmd", "url": "https://drug-cost.warondisease.org/references.html", "title": "Source Quotes and References", "description": "Every claim in this manual has a receipt. 347 sources, because 'trust me, I'm an alien' is not a citation format your species recognizes.", "image": "https://drug-cost.warondisease.org/assets/og-images/knowledge/references-og-bw-academic.jpg", "tags": [ "references" ], "published": true, "lastmod": "2026-03-03" } ], "pageCount": 3 }, { "id": "iab", "type": "website", "title": "Incentive Alignment Bonds: Making Public Goods Financially and Politically Profitable", "description": "Government spending is optimized for lobbying intensity, not net societal value. Programs with 100:1 benefit-cost ratios get billions while programs with negative returns get hundreds of billions. Incentive Alignment Bonds flip this by creating a capital pool that rewards politicians (via campaign support and post-office opportunities) for funding high-NSV programs over low-NSV alternatives. The result: public good becomes private profit for both investors and elected officials.", "siteUrl": "https://iab.warondisease.org", "favicon": "https://iab.warondisease.org/assets/icons/iab-favicon.png", "ogImage": "https://iab.warondisease.org/assets/og/iab-og-1200x630.jpg", "pdfUrl": "https://iab.warondisease.org/incentive-alignment-bonds-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18203221", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Mechanism Design, Public Choice, Political Economy, Collective Action, Campaign Finance", "category": "Academic Paper, Political Economy, Mechanism Design, Public Policy", "keywords": [ "mechanism-design", "public-choice", "political-economy", "collective-action", "social-impact-bonds", "campaign-finance", "incentive-compatibility", "incentive-alignment", "public-goods", "net-societal-value", "PAC", "lobbying" ], "audience": "Researchers, Policy Makers, Political Scientists, Economists, Political Reform Advocates", "format": "Working Paper", "genre": "Political Science, Economics, Mechanism Design, Public Policy", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "8f7611db-1075-48a2-abd8-7f77f55538f9", "cname": "iab-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/incentive-alignment-bonds-paper.qmd", "outputDir": "_site/iab", "publishing": { "ownSite": { "url": "https://iab.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522040", "doi": "10.5281/zenodo.18203221" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Public Choice", "tier": 2, "status": "target", "url": "" }, { "name": "American Economic Review", "tier": 1, "status": "target", "url": "" }, { "name": "Journal of Political Economy", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/incentive-alignment-bonds-paper.qmd", "url": "https://iab.warondisease.org/appendix/incentive-alignment-bonds-paper.html", "title": "Incentive Alignment Bonds: Making Public Goods Financially and Politically Profitable", "description": "Government spending is optimized for lobbying intensity, not net societal value. Programs with 100:1 benefit-cost ratios get billions while programs with negative returns get hundreds of billions. Incentive Alignment Bonds flip this by creating a capital pool that rewards politicians (via campaign support and post-office opportunities) for funding high-NSV programs over low-NSV alternatives. The result: public good becomes private profit for both investors and elected officials.", "image": "https://iab.warondisease.org/assets/og-images/knowledge/appendix/incentive-alignment-bonds-paper-og-retro-academic.jpg", "sections": [ "Introduction", "The Information-Incentive Disconnect", "Key Results", "Reader's Guide", "Definition", "Why Reallocation, Not Addition", "Political Change as an Asset Class", "The Capital Asymmetry: Why IABs Can Outcompete Incumbent Lobbying", "Quantifying Net Societal Value of Funding Sources", "Relation to Existing Literature", "Contribution", "Roadmap", "Why Previous Approaches Failed", "Mechanism Design Theory", "Public Choice Theory", "Social Impact Bonds", "Campaign Finance and Political Behavior", "Credit Rating Agencies as Governance Mechanisms", "The Math: Proving It Works", "Assumptions", "The Politician's Utility Function", "The Utility Function Transformation", "Numerical Calibration and Parameter Ranges", "The Policy Choice", "The Pre-IAB Equilibrium", "The IAB Mechanism", "Score-Dependent Payoffs", "Incentive Compatibility", "Nash Equilibrium Analysis", "Illustrative Example: A Global Health Treaty", "Calibration: Parameter Ranges for Incentive Compatibility", "How IABs Work in Practice", "Layer A: Scoring (Data Provision)", "Layer B: Electoral Support", "Layer C: Post-Office Benefits", "Why This Is Not Bribery", "Legal Entity Separation", "Funding Sources and Foundation Investment", "What Could Go Wrong", "Gaming and Metric Corruption", "Plutocracy Objection and the \"Lobbying With Extra Steps\" Critique", "Unintended Consequences", "Where IABs Fit in Democratic Reform", "The Four-Layer Governance Stack", "Comparison to Alternative Governance Mechanisms", "What IABs Do Not Solve", "Beyond Health: Climate, Nuclear Risk, and More", "The General Template", "Candidate Domains", "Welfare Accounting of the IAB Mechanism", "Conclusion", "The Bootstrap Problem and Regulatory Resistance", "Dominant Assurance Contract for Investor Coordination", "References", "Appendix A: Formal Proofs", "Proof of Proposition 1 (Sufficient Condition for Incentive Compatibility)", "Proof of Corollary 1 (Funding Threshold)", "Proof of Proposition 2 (Multiple Equilibria Without IABs)", "Proof of Proposition 3 (Equilibrium Selection With IABs)", "Proof of Proposition 4 (Investor Participation as Dominant Strategy)", "Proof of Corollary 2 (Full Participation Equilibrium)", "Appendix B: Detailed Application Specifications", "Climate Change", "Nuclear Disarmament", "Pandemic Preparedness", "Comparative Analysis" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://iab.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "invisible-graveyard", "type": "website", "title": "The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag", "description": "After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102 million deaths among people waiting for approved drugs (1962-2024). The human cost in death and disability of blocking good drugs is 3.07k higher than the cost of approving bad ones.", "siteUrl": "https://invisible-graveyard.warondisease.org", "favicon": "https://invisible-graveyard.warondisease.org/assets/icons/invisible-graveyard-favicon.png", "ogImage": "https://invisible-graveyard.warondisease.org/assets/og/invisible-graveyard-og-1200x630.jpg", "pdfUrl": "https://invisible-graveyard.warondisease.org/invisible-graveyard.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18356231", "version": "1.0", "edition": "Working Paper", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Regulatory Economics, FDA Policy, Drug Lag, Mortality Analysis, Cost-Benefit Analysis", "category": "Academic Paper, Health Economics, Regulatory Policy, Public Health", "keywords": [ "fda-regulation", "drug-lag", "kefauver-harris-amendments", "regulatory-delay", "type-ii-errors", "mortality-analysis", "cost-benefit-analysis", "pharmaceutical-regulation", "dalys", "efficacy-requirements", "peltzman", "regulatory-economics" ], "audience": "Regulatory Economists, Health Policy Researchers, FDA Reform Advocates, Public Health Officials, Pharmaceutical Industry Analysts", "format": "Working Paper", "genre": "Health Economics, Regulatory Policy, Cost-Benefit Analysis", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "ef37ca63-13e5-4403-bf47-173763af79ab", "cname": "invisible-graveyard-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/invisible-graveyard.qmd", "outputDir": "_site/invisible-graveyard", "publishing": { "ownSite": { "url": "https://invisible-graveyard.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18356231", "doi": "10.5281/zenodo.18356231" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "medrxiv", "status": "pending", "url": "" } ], "journals": [ { "name": "Journal of Law and Economics", "tier": 1, "status": "target", "url": "" }, { "name": "Regulation (Cato Institute)", "tier": 2, "status": "target", "url": "" }, { "name": "Health Economics", "tier": 2, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/invisible-graveyard.qmd", "url": "https://invisible-graveyard.warondisease.org/appendix/invisible-graveyard.html", "title": "The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag", "description": "After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102 million deaths among people waiting for approved drugs (1962-2024). The human cost in death and disability of blocking good drugs is 3.07k higher than the cost of approving bad ones.", "image": "https://invisible-graveyard.warondisease.org/assets/og-images/knowledge/appendix/invisible-graveyard-og-retro-academic.jpg", "tags": [ "appendix", "analysis", "fda", "regulatory-economics", "mortality", "cost-benefit" ], "sections": [ "The Short Version", "Abstract", "Scale", "Introduction", "Literature Review: The Drug Lag Debate", "Foundational Economic Analysis", "The Current Debate", "Empirical Case Studies: Demonstrating the Causal Mechanism", "Methodology & Data", "Variable Definitions", "Theoretical Upper Bound: What's Eventually Preventable?", "Methodological Note: Distinguishing Current vs. Theoretical Preventability", "Data Sources & Parameterization", "Uncertainty Quantification Methodology", "Results: The Mortality Burden", "Primary Estimate", "Methodological Caveat: Cascade Assumption", "Morbidity Analysis: DALYs and QALYs", "Years of Life Lost (YLL)", "Years Lived with Disability (YLD)", "Cumulative DALY Burden", "Years Lived with Disability - Treatment Beneficiaries", "Distinction: Mortality vs. Morbidity Burden", "Economic Valuation", "Contextualizing the Loss", "Risk Analysis: The Type I vs. Type II Ratio", "Methodological Note: Steelmanning the FDA's Position", "The Risk Trade-off Ratio", "Acknowledging the Efficacy-as-Safety Argument", "Drugs Appropriately Caught by Phase II/III Trials", "Model Assumptions and Limitations", "Key Assumptions", "Sensitivity Analysis", "Limitations", "Policy Implications", "The False Trade-off", "The Bifurcated Alternative", "Expected Impact", "International Regulatory Comparison", "Critical Distinction: Efficacy Assessment Reordered, Not Eliminated", "Addressing Common Critiques", "\"The PRIMARY Estimate Is Too Speculative\"", "\"The 'Eventually Preventable' Estimate Is Theoretical\"", "\"Counterfactual Uncertainty - We Can't Know What Would Have Happened\"", "\"Confounding Factors - Other Changes in 1962\"", "\"This Ignores Safety - Deregulation Would Flood Markets with Dangerous Drugs\"", "Conclusion" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://invisible-graveyard.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "manual-paperback", "type": "book", "title": "How to End War and Disease", "description": "The Complete Idiot's Guide to Legally Bribing Your Way to Utopia", "siteUrl": "https://manual.WarOnDisease.org", "ogImage": "", "pdfUrl": "https://manual.WarOnDisease.org/How-to-End-War-and-Disease-Paperback.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "version": "1.0.0", "edition": "First Edition", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Public Health, Medical Research, Peace Economics, Health Economics, Policy Reform", "category": "Non-fiction, Public Policy, Health Economics, Peace Studies", "keywords": [ "war-on-disease", "1-percent-treaty", "medical-research", "public-health", "peace-dividend", "decentralized-trials", "dfda", "dih", "victory-bonds", "health-economics", "cost-benefit-analysis", "clinical-trials", "drug-development", "regulatory-reform", "military-spending", "peace-economics", "decentralized-governance", "wishocracy", "blockchain-governance", "impact-investing" ], "audience": "General Public, Policy Makers, Investors, Healthcare Professionals, Researchers", "format": "Book", "genre": "Public Policy, Health Economics, Peace Studies", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "indexSource": "index-manual.qmd", "outputDir": "_manual-paperback/warondisease", "pages": [ { "path": "index-manual.qmd", "url": "https://manual.WarOnDisease.org/index-manual.html", "title": "How to End War and Disease (for Busy People)", "description": "The Complete Idiot's Guide to Legally Bribing Your Way to Utopia", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/1-percent-treaty-og-retro-academic.jpg", "sections": [ "The Human Economy", "The Gradual Irrationality Reduction Program", "What to Do When They Try to Institutionalize You", "The Sacred Order of Paper Distribution", "Why Your Leaders Aren't the Problem", "Humanity's Death Wish", "The Problem", "The Daily Deletion Event", "The Unexplored Therapeutic Frontier", "The Cost of War", "Your Civilization Has a Countdown", "The FDA is Unsafe and Ineffective", "The Solution", "A 1% Treaty", "Your Decentralized FDA", "Why This Could Actually Work", "The Evidence", "The Math", "The 5-Step Plan", "Step 1: Sell Incentive Alignment Bonds", "Step 2: The Great Clicking", "Step 3: Bribe the Bribers", "Step 4: Purchase Democracy", "Step 5: Enjoy", "How This Manual Could Fix Everything", "Choose Your Own Adventure", "The Part Where Humanity Has No Choice" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/problem/genetic-slavery.qmd", "url": "https://manual.WarOnDisease.org/problem/genetic-slavery.html", "title": "Genetic Slavery", "description": "Your government spends 604 more on weapons than on curing disease, and you think that's a political problem. It's not. It's a hardware problem. You're running 200,000-year-old software optimized for hoarding rocks and fearing strangers, and you've given it nuclear weapons. This chapter is the owner's manual for the brain that's trying to kill you.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/genetic-slavery-og-retro-academic.jpg", "tags": [ "evolution", "psychology", "selfish-gene", "scarcity", "violence", "human-nature", "stupidity" ], "sections": [ "How Hydrogen Learned to Worry (A 13.8 Billion Year Recap)", "The Selfish Gene Made You Illogical (It Was a Good Idea at the Time)", "Part 1: Your Brain Was Optimized for a World That Doesn't Exist", "The Violence Module (Or: Why You Tend to Prefer Bombs Over Clinical Trials)", "The Tribal Brain (Or: Why Democracy Was Always Going to Be a Mess)", "The Compassion Gradient (Or: Why You'll Buy Your Cat a Birthday Cake While Children Starve)", "Your Brain Is a Museum of Obsolete Instincts", "Part 2: Genetic Slavery is Literally Killing You", "Part 3: Why You Can't Just \"Be Better\"", "Part 4: Breaking the Chains" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem/fda-is-unsafe-and-ineffective.qmd", "url": "https://manual.WarOnDisease.org/problem/fda-is-unsafe-and-ineffective.html", "title": "Your FDA Is Unsafe and Ineffective", "description": "A drug passes every safety test your species invented. It won't hurt you. Everyone agrees. You still can't have it for another 8.2 years. There is, however, no waiting list for dying. No one blocks that. The testing costs 44.1x more than proven alternatives and excludes 86.1% of the patients who'll actually take it. For every 1 unit of harm prevented, the system creates 3.07k through denied access. Here's how to fix it.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/fda-is-unsafe-and-ineffective-og-retro-academic.jpg", "tags": [ "problem", "fda", "clinical-trials", "drug-approval", "bureaucracy", "regulatory-capture" ], "sections": [ "A Note on Blame", "\"But What About Safety?\"", "The 44.1x Inefficiency Tax", "The 8.2 years Efficacy Lag", "What the 1962 Efficacy Requirements Changed", "The Modern Consequences", "Off-Patent Drugs and Rare Diseases: Mathematically Doomed", "The Actual Death Toll of \"Drug Lag\"", "How the Incentives Work", "FDA Regulator Decision Tree", "The Math: Why Current Regulations Increase Total Harm", "Clinical Trial Theater: Excluding 86.1% of Reality Makes Drugs More Dangerous", "No Long-Term Outcome Data", "Pre-Specification Requirements Kill Innovation", "The Blinding Catch-22: How Knowing a Drug Works Proves It Doesn't", "Small Trials Are Dangerous", "The Negative Results Black Hole", "Countries That Don't Have Our \"Safety\"", "The COVID Test Fiasco", "The Bottom Line", "Technical Analysis" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem/nih-fails-2-institute-health.qmd", "url": "https://manual.WarOnDisease.org/problem/nih-fails-2-institute-health.html", "title": "NIH Fails to Institute Health", "description": "A root cause failure analysis to show why the world's largest medical research institution only allocates 3.3% of its budget to testing which of the thousands of known-safe treatments actually work in humans. Oxford tested COVID treatments for $500 per patient and saved a million lives in 100 days. The NIH spent $1.6 billion and completed zero trials in four years.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/nih-spent-1-trillion-eradicating-0-diseases-og-retro-academic.jpg", "tags": [ "problem", "nih", "grants", "research-funding", "bureaucracy", "failure", "clinical-trials", "misallocation" ], "sections": [ "A Tale of Two Trials", "RECOVERY Trial (UK Approach)", "RECOVER Initiative (NIH Approach)", "The Translation Crisis: All Theory, No Medicine", "Plenty of Knowledge. No Translation.", "The Allocation Problem", "Why This Allocation Exists", "You Pay Twice", "The Patient Disconnect: Zero Correlation with Health Outcomes", "The Human Cost of Misallocation", "Cost Per Quality-Adjusted Life Year", "The Preventable Deaths", "The Track Record", "What Would Actually Work" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/problem/unrepresentative-democracy.qmd", "url": "https://manual.WarOnDisease.org/problem/unrepresentative-democracy.html", "title": "Unrepresentative Democracy", "description": "Your government spends 604 times more on weapons than on testing which medicines work. You could elect 535 Gandhis and within two years they'd be funding nuclear weapons programs, because the system requires it. Princeton studied 1,779 of your policy decisions and found that public opinion has the same effect on legislation as a houseplant. This chapter explains why you can't vote your way out, and why that's actually fine, because the solution was never better politicians.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/unrepresentative-democracy-og-retro-academic.jpg", "tags": [ "democracy", "public-choice-theory", "voting", "collective-action", "incentives", "politics" ], "sections": [ "What Democracy Looks Like From Space", "The Mathematics of Why Nobody Fixes Anything", "Concentrated Benefits vs. Diffuse Costs", "The Death Spiral: How Two Choices Kill 330 Million Options", "How Money Buys Your Government", "The Lobbying ROI: Better Than Every Other Investment", "Your Congressman: A Professional Fundraiser Who Occasionally Dabbles in Legislation", "Congressional Committees: The Menu", "Public Choice Theory (Or: The Nobel Prize for Cynicism)", "What Each Institution Actually Optimizes For", "The Misdiagnosis", "Regulatory Capture: How the Burglar Trained the Guard Dog", "The Self-Sustaining War Machine", "The Ratchet", "The Equilibrium", "The Solution They Don't Want You to Have" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/central-banks.qmd", "url": "https://manual.WarOnDisease.org/economics/central-banks.html", "title": "Money Comes From a Building and They Use It to Kill People", "description": "Your money is manufactured in a building by people you didn't elect. It has funded unpopular wars that killed 97 million people. They give it to their friends first, then use the rest to buy weapons you didn't ask for. By the time it reaches you, it buys less. This has been happening for a century. Nobody covers it on the news because it is, by design, extremely boring.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/central-banks-og-retro-academic.jpg", "tags": [ "central-banking", "war-funding", "monetary-policy", "federal-reserve", "inflation" ], "sections": [ "The Pattern: Print, Kill, Repeat", "The Roman Empire (3rd Century)", "Revolutionary France (1790s)", "Weimar Germany (1920s)", "The American Money Printer", "The Receipt", "What About Wars Under Hard Money?", "1971: The Day Your Money Stopped Meaning Anything", "Why He Did It", "What He Killed", "What Actually Happened", "The Dual Mandate (Or: The Two Goals of Serfdom)", "Goal 1: \"Maximum Employment\" (Keep Everyone Busy)", "Goal 2: \"Stable Prices\" (Take 2% Per Year)", "The \"Deflation Is Dangerous\" Story", "The One Data Point", "The \"Banking Panics\" Defense", "What They Could Measure Instead", "How the Robbery Works", "The Spread", "The 2020 Demonstration", "The Theft That Followed", "The Two-Income Trap", "The Time They Broke It", "Your 93% Pay Cut (Measured in Shiny Rocks)", "Why Nobody Told You", "\"But It Wasn't the Gold Standard, It Was...\"", "Why You Don't Know Any of This", "Same Trick, Different Costume", "The Priesthood", "The Fake Nobel Prize", "The Research", "Why \"Just Print More Money for Medicine\" Doesn't Work", "The Fixed Pie of Human Genius", "The Shell Game (How Inflation Steals Medical Progress)", "The Proof: 50 Years of Going Nowhere", "\"Just Tax the Billionaires\"", "Why Money Printing Matters: Geniuses Follow the Money", "The Two Receipts", "Receipt 1: What the Printer Killed", "Receipt 2: What the Printer Wasted", "The Ask" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/problem/untapped-therapeutic-frontier.qmd", "url": "https://manual.WarOnDisease.org/problem/untapped-therapeutic-frontier.html", "title": "The Untapped Therapeutic Frontier", "description": "There are 9.5 million possible drug-disease combinations. You've tested 32,500. That's like searching for your keys in 0.34% of your house and declaring them lost. The other 99.7% is sitting right there, untested, because the molecules weren't profitable enough to bother.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/untapped-therapeutic-frontier-og-retro-academic.jpg", "tags": [ "problem", "drug-discovery", "chemical-space", "clinical-trials", "repurposing", "opportunity" ], "sections": [ "How You Accidentally Cured Three Things and Then Stopped", "Your Medicine Cabinet (After 5,000 Years of Civilization)", "Ways Your Body Breaks (The To-Do List Nobody's Doing)", "The Multiplication Problem", "What You've Actually Tried", "The Number That Should Keep You Awake", "\"Maybe the Other 99.66% Is Useless\"", "Beyond Your Cupboard (Where It Gets Embarrassing)", "Why You Are Still Sick (A Diagnosis)", "The Timeline (How Long Until You Finish Looking)", "\"But Won't We Run Out of Easy Discoveries?\"", "What Happens When You Actually Try", "The Bottom Line" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/1-percent-treaty.qmd", "url": "https://manual.WarOnDisease.org/solution/1-percent-treaty.html", "title": "A 1% Treaty", "description": "You have enough nuclear weapons to kill everyone 13 times. Here's how to settle for 12.87 times and use the savings on medicine. Controversial, apparently.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/1-percent-treaty-og-retro-academic.jpg", "tags": [ "solution", "1-percent-treaty", "dih", "peace-dividend", "national-security", "mutual-survival" ], "sections": [ "How It Works", "This Isn't a Trade-Off", "Why Your Most Expensive Things Are Also Your Most Useless Things (A Mystery)", "The Blueprint", "What Each Country Pays", "National Security (Which Is What You Call It When You Spend Money on Things That Don't Make You Secure)", "Real Threats (That Actually Kill People)", "Overfunded Threats (That Countries Spend Trillions On)", "The Rebranding Campaign: From \"Weakness\" to \"Strategic Genius\"", "\"The Strategic Health Defense Initiative\"", "The Talking Points That Make Hawks Sound Like Doves", "The Money Flow", "The 1% Treaty Fund", "Year One Projected Outcomes", "The Incentive Structure", "What Happens If This Actually Works", "The Endgame", "The Ratchet Effect", "Avoiding Treaty Pitfalls", "Reservation Games", "Ratification Delays", "Creative Accounting", "Parliamentary Obstacles", "Summary", "Addendum: The Actual Treaty Text (First Draft)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/dih.qmd", "url": "https://manual.WarOnDisease.org/solution/dih.html", "title": "Decentralized Institutes of Health", "description": "Your military-industrial complex solved coordination for killing: weapons manufacturers, generals, politicians, and factory workers all profit from the same budget, so they all show up. Disease has no such coalition. Your Decentralized Institutes of Health builds one. It does three things: receive treaty funds, allocate them via patient choice and wishocratic voting, and pay based on results instead of grant applications. It's SHAEF for the war on disease. Same selfishness as the military-industrial complex, but pointed at biology instead of each other. Nobody gets paid for writing essays about why they should be allowed to try curing things. They get paid for curing things.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/dih-og-retro-academic.jpg", "tags": [ "solution", "dih", "governance", "funding-model", "coordination" ], "sections": [ "The Health-Industrial Complex: Coordinating Your War on Disease", "The Olsonian Problem", "SHAEF for Your War on Disease", "The ROI Maximization Protocol", "Pay for Results (A Concept Your Research Sector Has Somehow Avoided)", "Your Data Commons: Publish Everything", "Governance: Sick People Choose, Everyone Else Votes", "Making Selfishness Cure Disease", "How Your Researchers Get Paid", "How It Works For Your Patients", "How the Money Flows", "The Architecture", "The Fund Flow", "What Gets Funded: Market Failures Only", "What Your Decentralized Institutes of Health Outsources (Everything)", "Anti-Capture Design", "Security: Defense in Depth", "What You've Just Read" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/dfda.qmd", "url": "https://manual.WarOnDisease.org/solution/dfda.html", "title": "A Decentralized FDA", "description": "On Wishonia, you type in what's wrong with you, see what worked for everyone else, and try it. The outcomes get recorded automatically. We've had this for millennia. Your decentralized FDA is the same thing, built with technology you already have. It's an open protocol that connects treatments to patients, records what actually happens, and publishes the results. Consumer Reports, but for not dying. It cuts trial costs from $41K to $929, expands capacity from 1.9 million patients/year to 23.4 million patients/year, and replaces your 40-page drug inserts with Outcome Labels that tell you what actually happened to real humans who took the pill.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/dfda-og-retro-academic.jpg", "tags": [ "overview", "dfda", "bureaucratic-murder", "death-by-clipboard" ], "sections": [ "The Solution: Consumer Reports for Drugs", "How It Works: Just Let People Try Stuff (Carefully)", "The Power of Real-World Evidence (Or: Spying on Sick People for a Good Cause)", "The Two-Stage Pipeline: Watch First, Then Test", "Proof It Works (While the FDA Wasn't Looking)", "The Oxford Recovery Trial: How the British Accidentally Saved Medicine", "What You'd See: FDA.gov 2.0", "Step 1: Type in What's Killing You", "Step 2: See What Actually Works (Based on Reality, Not Theory)", "Step 3: Join a Trial from Your Couch (While Dying Comfortably)", "Step 4: Get Drugs Delivered Like Pizza (But More Life-Saving)", "Step 5: Publish Results", "Step 6: Everyone Benefits from Everyone's Suffering", "Outcome Labels: Nutrition Facts for Drugs", "Your Personal Death-Prevention Assistant: The FDAi", "Making It Legal to Not Die", "The Business Model: How Everyone Profits Except Disease", "How Companies Register Treatments (5 Minutes, Zero Approval Needed)", "The Payment Flow", "Why This Creates Vastly More Research Capacity", "The Money Shot: How to Save 95% on Not Killing People", "The Itemized Receipt of Eliminated Stupidity", "The Partnership Approach: Building Rails, Not Trains", "The Players Already in the Game", "Federated, Not Centralized", "Why This Works: The Mathematical Impossibility of Committees", "The Future: Where Death Becomes Embarrassing", "2027: The Beginning of the End of Dying Slowly", "2030: Big Pharma Pivots or Dies", "2035: The Great Revelation", "2050: Death Becomes Opt-In", "How Your Decentralized FDA Actually Works" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/aligning-incentives.qmd", "url": "https://manual.WarOnDisease.org/solution/aligning-incentives.html", "title": "Aligning Incentives", "description": "Pharmaceutical companies make more money treating you forever than curing you once. Defense contractors earn $1,425 per lobbying dollar. Nobody is evil. The incentives are. Rearrange the profit motive so curing disease pays better than causing it, and watch capitalism accidentally save your species.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/aligning-incentives-og-retro-academic.jpg", "sections": [ "Defense Contractors: Teaching Merchants of Death to Love Life", "The Offer", "The Math", "Why They Take It", "What You're NOT Asking", "Why This Works", "The Timeline", "Insurance Companies: The Accidentally Aligned Industry", "Their Current Death Spiral", "Your Salvation Offer", "Why They're Your Natural Allies", "Pharmaceutical Companies: Converting Drug Dealers to Drug Curers", "Their Current Trap", "The Math That Converts Them", "Pharma's New Business Model: Volume Over Blockbusters", "How to Get Them Onboard", "Politicians: Hacking Democracy's Source Code", "Their Current Misery", "Your Political Welfare Program", "The Bipartisan Beauty", "Billionaires: Self-Interest Meets Self-Preservation", "The Domino Effect", "Why This Can Work: The Coordination Problem Has a Price Tag", "Why This Scales: The Ratchet Effect" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/incentive-alignment-bonds.qmd", "url": "https://manual.WarOnDisease.org/solution/incentive-alignment-bonds.html", "title": "Incentive Alignment Bonds", "description": "War bonds, but backwards. Your grandparents funded WW2 at roughly 3% returns. You fund disease eradication at 272%. Same structure, fewer Nazis, better spreadsheet.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/incentive-alignment-bonds-og-retro-academic.jpg", "tags": [ "financial-instruments", "mechanism-design", "governance-innovation", "economics", "fundraising", "bond-structure", "campaign-finance", "capital-raising" ], "sections": [ "The Core Problem: Good Ideas Die in Committee", "How IABs Work (Four Steps)", "The Three-Layer Architecture (How to Not Go to Prison)", "Worked Example: How Senator Smith Votes Yes", "The Revenue Split", "Why 10% Goes to Political Incentives", "Beyond the 1% Treaty", "For Investors", "The Investor Pitch", "The Perpetuity Math", "Security Package and Risk", "How It Compares (If It Works)", "Investment Thresholds and Term Sheet", "Summary" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/solution/optimocracy.qmd", "url": "https://manual.WarOnDisease.org/solution/optimocracy.html", "title": "Optimocracy: The Evidence Machine", "description": "On Wishonia, the Optimitron comes free with your first government. Its Optimal Budget Generator (OBG) and Optimal Policy Generator (OPG) check which policies work by looking at the 10,000 places that already tried them. Your species skipped this step and went straight to arguing.", "image": "https://manual.WarOnDisease.org/assets/images/optimocracy-paper/optimocracy-paper-section-the-mechanism-bw-academic.jpg", "tags": [ "solution", "optimocracy", "governance", "causal-inference", "evidence-based-policy", "capture-resistance" ], "sections": [ "The Only Two Numbers That Matter", "The Price of Not Checking", "The Answer Key You Already Have", "Why Knowing Isn't Enough", "The Mechanism: Recommend, Track, Reward", "Corruption, But Make It Difficult", "Putting It Together" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/solution/wishocracy.qmd", "url": "https://manual.WarOnDisease.org/solution/wishocracy.html", "title": "Wishocracy", "description": "How to let billions of people say whether the next marginal public dollar should buy another nuclear weapon system or fund another pragmatic clinical trial, without routing the answer through lobbyists, committees, and middlemen.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/wishocracy-og-retro-academic.jpg", "tags": [ "solution", "wishocracy", "governance", "ai", "collective-intelligence", "resource-allocation", "democracy-but-working" ], "sections": [ "How Wishocracy Allocates High-Level Priorities", "What Wishocracy Actually Decides:", "How It Works: Pairwise Slider Allocation", "Why This Actually Works (Math Warning)", "\"But Direct Democracy Has Been Tried\" (Yes. Badly.)", "Your Current System Is Phone-a-Friend (But Your Friend Is Being Bribed)", "The 26-Point Gap Is a Floor, Not a Ceiling", "Why Markets Solved This (and Why You Still Need Wishocracy)", "From Priorities to Projects (Where Wishes Become Tasks)", "Why the Algorithm Is the Constitution", "Algorithmic Protections (Rules Nobody Can Break Because They're Not Rules)", "What Wishocracy Measures" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/proof/body-as-repairable-machine.qmd", "url": "https://manual.WarOnDisease.org/proof/body-as-repairable-machine.html", "title": "You Are a Meat Robot", "description": "The usual objection to curing all disease is that it's impossible. You replace 330 billion cells a day. You 3D-print windpipes. You reprogram skin into brain cells. You've already proven your body is a machine, and machines are repairable. The only reason you haven't repaired it is that you spent the repair budget on missiles. This chapter removes the \"impossible\" objection so you can get back to the \"expensive\" objection, which the treaty solves.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/proof/body-as-repairable-machine-og-retro-academic.jpg", "tags": [ "biology", "aging", "regenerative-medicine", "repair", "engineering", "proof", "car-analogy" ], "sections": [ "Death is a Technical Problem", "You Are a Self-Repairing Meat Robot", "You've Already Started Fixing the Machine", "Exhibit A: You Can Grow New Parts", "Exhibit B: You Can Reprogram Your Cells", "Exhibit C: You're Debugging Your Code", "The Car Restoration Analogy", "The Proof That Aging is Reversible", "Nature Already Does It", "You've Already Reversed Aging (In Mice... and Human Cells)" ], "published": true, "lastmod": "2026-03-07" }, { "path": "knowledge/futures/moronia.qmd", "url": "https://manual.WarOnDisease.org/futures/moronia.html", "title": "The Cautionary Tale of Moronia", "description": "A planet had every tool needed to cure disease and chose to build weapons instead. They went extinct. Their last words were 'but the economy.' This is a bedtime story for civilizations that can't do math.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/futures/moronia-og-retro-academic.jpg", "tags": [ "dystopia", "moronia", "ai-weapons", "collapse" ], "sections": [ "The Discovery", "What I Tried to Tell Them", "The Cascade", "Year Zero: Already Broken (Much Like You)", "The Spiral (Already in Progress)", "The Warehouses", "The Ratchet", "Years 1-5: The Acceleration", "The Weapons Speak", "The Logic Trap", "Everything Dies", "The Mirror" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/futures/wishonia.qmd", "url": "https://manual.WarOnDisease.org/futures/wishonia.html", "title": "Wishonia", "description": "On one planet, citizens allocate the budget directly, lobbyists don't exist, and disease was eradicated 4,000 years ago. It uses the same technology you have. The difference is they pointed it at biology instead of each other.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/futures/wishonia-og-retro-academic.jpg", "tags": [ "utopia", "future", "peace-dividend", "post-scarcity", "health", "happiness" ], "sections": [ "What the Optimized World Looks Like", "Biology Becomes Software", "A Day in the Optimized Life", "The Diseases That Stopped Existing", "The Peace Dividend Economy", "Your Corporate Heroes", "Our Current Problems", "What Fixing Health Fixed", "Climate", "Poverty", "Science", "Peace and Governance", "Happiness", "Freedom", "The Three Supers Complete", "Your Personal Future", "What Comes After", "Your Two Paths" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/faq.qmd", "url": "https://manual.WarOnDisease.org/appendix/faq.html", "title": "Frequently Asked Objections", "description": "Fun facts for those reasonably skeptical of spending 1% more on helping sick people than killing them.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/faq-og-retro-academic.jpg", "sections": [ "\"We Need the Military Budget\"", "\"Big Pharma Will Block This\"", "\"What About National Sovereignty?\"", "\"The FDA Exists for a Reason\"", "\"What If Countries Cheat?\"", "\"You Can't Cure Aging\"", "\"I'm Just One Person\"", "\"Why Not Just Reform the System?\"", "\"This Is Politically Impossible\"", "\"What If the Science Is Wrong?\"", "\"War Is Human Nature\"", "\"All Wars on X Have Failed\"", "\"This Sounds Like Bribery\"", "\"Why Not Just Use Philanthropy?\"", "\"84 Quadrillion Dollars Is a Made-Up Number\"", "\"How Do You Prevent Waste?\"" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/strategy/roadmap.qmd", "url": "https://manual.WarOnDisease.org/strategy/roadmap.html", "title": "The Roadmap to End War and Disease", "description": "This isn't a protest. It's a recipe. Step one, collect papers from rich humans (using greed). Step two, get 280 million humans to click a button (using paid referral bonuses, because your species won't save itself for free). Step three, apply papers to politicians until the treaty happens (using the only language they understand). Every step has a budget, a timeline, and a contingency plan for the fact that you're you.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/roadmap-og-retro-academic.jpg", "tags": [ "roadmap", "strategy", "timeline", "execution-plan", "finance", "operations", "nonprofit", "victory-bonds", "referendum", "lobbying" ], "sections": [ "High-Level Strategy: The Three-Step Recipe for Not Dying", "Step 1: Collect Papers from Rich People", "Step 2: Tell Humans the Referendum Exists", "Step 3: Apply Papers to Politicians Until Treaty Happens", "The Sacred (Legal) Bribery Sequence", "(Legal) Bribe Category #1: Rich People (The Paper Collectors)", "(Legal) Bribe Category #2: The True Believers (Early Adopters)", "(Legal) Bribe Category #3: Regular People (Everyone Else)", "(Legal) Bribe Category #4: Politicians (The Elected Paper Recipients)", "The Success Spiral", "The Timeline: From $0 to Ending Death", "The Legal Architecture: How to Be a Charity, a Lobbying Group, and a Hedge Fund Simultaneously", "Phase 4+: The Expansion Phases (Years 4-50)", "Why Expansion Is Built Into The System", "Here's Why It Keeps Growing", "The Endgame" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/strategy/global-referendum.qmd", "url": "https://manual.WarOnDisease.org/strategy/global-referendum.html", "title": "Global Referendum Strategy", "description": "Humanity downloaded TikTok over 4 billion times to watch strangers twerk. Getting 280 million people to click 'yes' on not dying should be easier. Here's how, with math.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/global-referendum-og-retro-academic.jpg", "tags": [ "referendum", "governance", "identity", "verifiability", "privacy", "security", "viral-marketing", "fraud-prevention" ], "sections": [ "What You're Actually Building", "The Goal", "The Voting System", "On Stopping People from Cheating", "Growth Strategy", "Integrity (Proving You Didn't Cheat)", "Implementation Roadmap", "Success Metrics", "On Why 3.5% Is The Magic Number", "The Bottom Line" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/appendix/treaty-feasibility.qmd", "url": "https://manual.WarOnDisease.org/appendix/treaty-feasibility.html", "title": "Treaty Feasibility & Cost Analysis", "description": "Previous treaties failed because they ran on guilt. Guilt has terrible fuel efficiency. This one runs on greed, which is (regrettably) humanity's only reliable fuel source.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/treaty-feasibility-og-retro-academic.jpg", "tags": [ "treaty", "diplomacy", "cost-analysis", "feasibility", "history" ], "sections": [ "What Treaties Actually Cost", "Inflation-Adjusted to 2024 Dollars", "Cost for a 1% Health Treaty", "The Math", "How to Make Governments Sign Things", "Timeline to \"Governments Can't Ignore This\"", "Political Success Probability: Economic Analysis", "Historical Precedents (The Depressing Table)", "Why a 1% Treaty is Harder Than Most Precedents", "Why a 1% Treaty Might Beat the Odds", "Probability Estimates", "Expected Value (Even When You Assume Failure)", "The Chain Reaction Model: Why This Idea Cannot Stay Contained", "Direct Encounters", "The Mathematics", "The Decision-Theoretic Case: Why Rational Actors Eventually Move", "The Incentive Structure", "Why the EV Is Not Just Moral", "Why This Should Matter Even to a Self-Interested Billionaire", "Conditional Near-Inevitability Claim", "Minimal Launch Probability Model", "Why Delay Becomes Irrational", "What Would Have To Be Wrong", "Why This Still Feels Inevitable", "Why The Treaty Won't Stop at 1%", "The Expansion Mechanism", "Why This Differs from Every Other Treaty", "The Ratchet Effect", "Long-Term Feasibility" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/economics/peace-dividend.qmd", "url": "https://manual.WarOnDisease.org/economics/peace-dividend.html", "title": "Peace Dividend", "description": "Your government spends more on camouflage paint than on curing Alzheimer's. Move 1% of the bomb budget to medicine: $27.2 billion for clinical trials, plus $114 billion saved by slightly fewer explosions. The worst-case scenario is still the largest increase in medical research in history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/peace-dividend-og-retro-academic.jpg", "tags": [ "peace-dividend", "1-percent-treaty", "economic-analysis", "cost-of-war" ], "sections": [ "How 1% Less Violence Pays For Everything", "The Captured Money: $27.2B/Year", "The Bonus Savings: $114B/Year", "Where the $114B Comes From", "The Two Numbers", "The Elasticity Question", "The Part Where the Math Gets Embarrassing", "What You're Assuming (and Where It Gets Shaky)", "The GDP Multiplier", "The Elasticity Assumption", "How Good Are the Sources?", "The Safe Bet", "The Trajectory, Not the Snapshot", "Two Futures" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/gdp-trajectories.qmd", "url": "https://manual.WarOnDisease.org/economics/gdp-trajectories.html", "title": "Two Paths: GDP Trajectories", "description": "Your economists project 2.5% annual growth. This requires 20 consecutive years of nothing going wrong, which your species has never achieved. Meanwhile your destructive economy (military spending plus its cybercrime offspring) is already 11.5% of GDP and growing faster than your actual economy. The Soviet Union collapsed at 15-18%. This chapter models two paths, the one you're on and the one where you redirect the murder budget. One ends with average income at $339K. The other ends with cockroaches finding this manual.", "tags": [ "gdp-trajectories", "economic-analysis", "peace-dividend", "expected-value", "current-trajectory", "wishonia", "cybercrime", "military-spending" ], "sections": [ "Two Paths", "Your Current Trajectory", "So How Long Do You Have?", "You Already Know What This Looks Like", "What We Did Instead", "The Decision", "What This Means Per Person", "Go Ahead, Change the Numbers" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/economics/health-dividend.qmd", "url": "https://manual.WarOnDisease.org/economics/health-dividend.html", "title": "Health Dividend", "description": "6.65 thousand diseases have zero approved treatments. At your current pace, you'll get to all of them in 443 years. Redirect 1% of military spending and it drops to 36 years, preventing 10.7 billion deaths at 50.3kx the cost-effectiveness of anti-malaria bed nets. The whole thing costs less per year to run than Halloween costumes for dogs. But sure, take your time.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/health-dividend-og-retro-academic.jpg", "tags": [ "dfda", "roi", "clinical-trials", "cost-reduction", "economics" ], "sections": [ "From Explosions to Trial Slots", "The Waiting List", "The Body Count", "The Price Tag on Not Being Dead", "The Receipt" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/financial-plan.qmd", "url": "https://manual.WarOnDisease.org/economics/financial-plan.html", "title": "Financial Plan", "description": "Most financial plans are complicated because the writers are confused or lying. This one has three steps. Raise $1B (using greed, not generosity, because greed is faster). Spend it to pass the treaty. Manage $27.2B a year forever, with 80% curing diseases, 10% paying investors, and 10% keeping politicians obedient. The corruption is capped at 20% and fully transparent, which already makes it the most honest government program in your country's history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/financial-plan-og-retro-academic.jpg", "tags": [ "finance", "overview", "strategy", "treasury-management" ], "sections": [ "Pillar 1: The Money Part (Raise $1B)", "Pillar 2: The Spending Part (Spend $1B)", "The Part That Makes It Cheap", "Pillar 3: The Forever Part (Manage $27.2B+/Year)", "How the Money Gets Spent: 80/10/10", "Dynamic Patient Subsidies", "The Whole Thing on One Line" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/strategy/nonprofit-coalition-strategy.qmd", "url": "https://manual.WarOnDisease.org/strategy/nonprofit-coalition-strategy.html", "title": "Why Every Nonprofit Should Support a 1% treaty", "description": "Nonprofits fighting disease currently compete for the same shrinking pile of donor money. A 1% treaty creates $27.2 billion in new funding. Every charitable organization can stop fighting over crumbs and start fighting for the bakery, if someone tells them the bakery exists.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/nonprofit-coalition-strategy-og-retro-academic.jpg", "tags": [ "strategy", "nonprofits", "coalition", "resource-allocation", "1-percent-treaty", "game-theory" ], "sections": [ "Why the Banquet Exists and Nobody Has Noticed", "\"But Shouldn't Nonprofits Focus on Their Core Mission?\"", "The Obvious Solution That Nobody Sees", "Why Your Species Only Changes When the Building Is On Fire", "The Factory Precedent", "\"Why Not Just Run Trials Without the Treaty?\"", "What 1% Less Violence Buys Every Mission", "On Bribing Nonprofits (Legally)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/legal/legal-framework.qmd", "url": "https://manual.WarOnDisease.org/legal/legal-framework.html", "title": "Legal Architecture", "description": "Bribing politicians is illegal unless you call it 'lobbying' or 'campaign contributions.' Then it's protected speech. Here's the legal architecture for saving humanity using your own ridiculous laws.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/legal/legal-framework-og-retro-academic.jpg", "tags": [ "legal-framework", "compliance", "securities-law", "election-law", "multi-jurisdiction", "organizational-structure" ], "sections": [ "Entity #1: Your 501(c)(3) Public Charity (\"The Brain\")", "Entity #2: Your 501(c)(4) Social Welfare Org (\"The Sword\")", "Entity #3: The Victory Corporation (\"The Engine\")", "Entity #4: Your Decentralized Institutes of Health Foundation (\"The Soul\")", "Why One Organization Pretending to Be Four", "The General Staff", "Securities Law (A Section Named After Oranges)", "Election Law (A Section About Legal Bribery)", "Treaty Framework", "Risk Mitigation (When They Come For You)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/appendix/recruitment-and-propaganda-plan.qmd", "url": "https://manual.WarOnDisease.org/appendix/recruitment-and-propaganda-plan.html", "title": "Recruitment & Propaganda Plan", "description": "You want to end war and disease but don't have a nonprofit, a bank account, or anything to offer anyone. Here's how to recruit 100,000 humans before you have anything except an argument. It's a Kickstarter where the reward tier is 'possibly not dying,' which is the most compelling crowdfunding offer in history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/recruitment-and-propaganda-plan-og-retro-academic.jpg", "tags": [ "operations", "fundraising", "recruitment", "strategy", "propaganda" ], "sections": [ "The Bureaucratic Nesting Doll Problem", "Three Types of Humans Who Want to Help", "Spreadsheet Humans (Investors)", "Heart Humans (Advocates)", "Institutional Humans (Partners)", "Phase 0: The Shopping List", "Getting Started (It Takes Twenty Minutes)", "The Comforting Asymmetry", "The Question You Can't Answer Wrong", "The Zero Percent Problem", "How Trivial, Exactly", "The Only Remaining Failure Mode", "Your Ammunition (Copy, Paste, Send)", "The Message", "Variations", "Which Message for Which Human" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/conclusion.qmd", "url": "https://manual.WarOnDisease.org/appendix/conclusion.html", "title": "Conclusion", "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/references.qmd", "url": "https://manual.WarOnDisease.org/references.html", "title": "Source Quotes and References", "description": "Every claim in this manual has a receipt. 347 sources, because 'trust me, I'm an alien' is not a citation format your species recognizes.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/references-og-bw-academic.jpg", "tags": [ "references" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/appendix/acknowledgments.qmd", "url": "https://manual.WarOnDisease.org/appendix/acknowledgments.html", "title": "Acknowledgments", "description": "Where Wishonia Begrudgingly Admits She Had Help", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/acknowledgments-og-retro-academic.jpg", "sections": [ "Translator", "Technical Contributors", "On Standing on Shoulders" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/appendix/copyright.qmd", "url": "https://manual.WarOnDisease.org/appendix/copyright.html", "title": "Copyright", "published": true, "lastmod": "2026-03-03" } ], "pageCount": 32 }, { "id": "manual", "type": "book", "title": "How to End War and Disease", "description": "The Complete Idiot's Guide to Legally Bribing Your Way to Utopia", "siteUrl": "https://manual.WarOnDisease.org", "favicon": "https://manual.WarOnDisease.org/assets/icons/book-favicon.png", "ogImage": "https://manual.WarOnDisease.org/assets/cover/book-cover-wide.png", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "version": "1.0.0", "edition": "First Edition", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Public Health, Medical Research, Peace Economics, Health Economics, Policy Reform", "category": "Non-fiction, Public Policy, Health Economics, Peace Studies", "keywords": [ "war-on-disease", "1-percent-treaty", "medical-research", "public-health", "peace-dividend", "decentralized-trials", "dfda", "dih", "victory-bonds", "health-economics", "cost-benefit-analysis", "clinical-trials", "drug-development", "regulatory-reform", "military-spending", "peace-economics", "decentralized-governance", "wishocracy", "blockchain-governance", "impact-investing" ], "audience": "General Public, Policy Makers, Investors, Healthcare Professionals, Researchers", "format": "Book", "genre": "Public Policy, Health Economics, Peace Studies", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "4e36b0d6-9b80-49e2-bf16-eb4d2f79f062", "cname": "manual-warondisease-org.netlify.app" }, "indexSource": "index-manual.qmd", "outputDir": "_manual/warondisease", "publishing": { "ownSite": { "url": "https://manual.WarOnDisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "pending", "url": "", "doi": "" }, { "platform": "amazon-kindle", "status": "pending", "url": "" }, { "platform": "apple-books", "status": "pending", "url": "" } ], "journals": [] }, "pages": [ { "path": "knowledge/links.qmd", "url": "https://manual.WarOnDisease.org/links.html", "title": "Select Your Preferred Sensory Input Channel", "description": "Humans require instructions delivered through specific orifices. Choose yours. Available via skull vibration ports, murdered trees, or glowing rectangles.", "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/podcast.qmd", "url": "https://manual.WarOnDisease.org/podcast.html", "title": "Skull Auditory Port Edition", "description": "Step-by-step instructions for bribing humanity into not murdering you, narrated directly into your head. Free on every app that puts sounds in your skull auditory ports.", "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem.qmd", "url": "https://manual.WarOnDisease.org/problem.html", "title": "Diagnostic Summary", "description": "A diagnostic survey of the systems that allocate your species' resources to killing instead of curing", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem-og-retro-academic.jpg", "tags": [ "problem", "war", "disease", "death", "military-spending", "healthcare", "democracy", "regulatory-capture" ], "sections": [ "The Daily Body Count", "Where the Money Goes", "On Medical Research", "On the FDA", "On What War Costs", "On What Disease Costs", "On Democracy", "On the Fixed Pie", "What's Next" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem/cost-of-war.qmd", "url": "https://manual.WarOnDisease.org/problem/cost-of-war.html", "title": "The Cost of War", "description": "Quantifying Human Idiocy - A precise accounting of what humans spend to destroy themselves, with numbers that would make a statistician weep.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/cost-of-war-og-retro-academic.jpg", "tags": [ "costs-of-war", "military-spending", "economic-analysis" ], "sections": [ "The Itemized Receipt for Armageddon", "The Shopping List (2024 Global Data)", "The Equation of Immediate Destruction", "Military Hardware: The World's Worst Investment", "The Dead Capital Problem", "The Price of a Ghost: Valuing Human Life", "Infrastructure Destruction: Building Things, Then Un-Building Them", "Reconstruction Cost Analysis (2023 Estimates)", "Economic Disruption: The Ripple Effect", "Trade Flow Disruption Matrix", "The Ghost in the Machine: Indirect Costs", "Opportunity Cost Analysis: The Roads Not Taken", "Long-term Human Costs: The Gift That Keeps on Taking", "Environmental Degradation: Poisoning the House You Live In", "The Existential Overdraft: The AI Arms Race", "The Total Cost of Organized Violence", "Comprehensive Cost Analysis (2024)", "For Context", "The Running Tab", "Hidden Costs of War" ], "published": true, "lastmod": "2026-03-07" }, { "path": "knowledge/problem/cost-of-disease.qmd", "url": "https://manual.WarOnDisease.org/problem/cost-of-disease.html", "title": "The Cost of Disease", "description": "The annual bill for letting your bodies fall apart. It's more than all the money on Earth, which is impressive in a terrible way.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/cost-of-disease-og-retro-academic.jpg", "tags": [ "problem", "disease", "economics", "cost-of-illness", "human-stupidity" ], "sections": [ "The Daily Body Count", "The Financial Cost", "The Actual Bill (Economist-Approved Misery Accounting)", "How to Measure Suffering Without Feeling Feelings (The DALY)", "What the WHO Thinks You're Worth (Less Than a Tesla)", "Let's Break Down This Apocalypse By Time Unit", "What's Actually Deleting Everyone (The Greatest Hits)", "Your Body Is Not Magic, It's Just Broken", "What This Actually Costs", "Your Priorities, Written in Your Budgets", "The Future You're Paying For" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/problem/nih-fails-2-institute-health.qmd", "url": "https://manual.WarOnDisease.org/problem/nih-fails-2-institute-health.html", "title": "NIH Fails to Institute Health", "description": "A root cause failure analysis to show why the world's largest medical research institution only allocates 3.3% of its budget to testing which of the thousands of known-safe treatments actually work in humans. Oxford tested COVID treatments for $500 per patient and saved a million lives in 100 days. The NIH spent $1.6 billion and completed zero trials in four years.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/nih-spent-1-trillion-eradicating-0-diseases-og-retro-academic.jpg", "tags": [ "problem", "nih", "grants", "research-funding", "bureaucracy", "failure", "clinical-trials", "misallocation" ], "sections": [ "A Tale of Two Trials", "RECOVERY Trial (UK Approach)", "RECOVER Initiative (NIH Approach)", "The Translation Crisis: All Theory, No Medicine", "Plenty of Knowledge. No Translation.", "The Allocation Problem", "Why This Allocation Exists", "You Pay Twice", "The Patient Disconnect: Zero Correlation with Health Outcomes", "The Human Cost of Misallocation", "Cost Per Quality-Adjusted Life Year", "The Preventable Deaths", "The Track Record", "What Would Actually Work" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/problem/untapped-therapeutic-frontier.qmd", "url": "https://manual.WarOnDisease.org/problem/untapped-therapeutic-frontier.html", "title": "The Untapped Therapeutic Frontier", "description": "There are 9.5 million possible drug-disease combinations. You've tested 32,500. That's like searching for your keys in 0.34% of your house and declaring them lost. The other 99.7% is sitting right there, untested, because the molecules weren't profitable enough to bother.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/untapped-therapeutic-frontier-og-retro-academic.jpg", "tags": [ "problem", "drug-discovery", "chemical-space", "clinical-trials", "repurposing", "opportunity" ], "sections": [ "How You Accidentally Cured Three Things and Then Stopped", "Your Medicine Cabinet (After 5,000 Years of Civilization)", "Ways Your Body Breaks (The To-Do List Nobody's Doing)", "The Multiplication Problem", "What You've Actually Tried", "The Number That Should Keep You Awake", "\"Maybe the Other 99.66% Is Useless\"", "Beyond Your Cupboard (Where It Gets Embarrassing)", "Why You Are Still Sick (A Diagnosis)", "The Timeline (How Long Until You Finish Looking)", "\"But Won't We Run Out of Easy Discoveries?\"", "What Happens When You Actually Try", "The Bottom Line" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem/fda-is-unsafe-and-ineffective.qmd", "url": "https://manual.WarOnDisease.org/problem/fda-is-unsafe-and-ineffective.html", "title": "Your FDA Is Unsafe and Ineffective", "description": "A drug passes every safety test your species invented. It won't hurt you. Everyone agrees. You still can't have it for another 8.2 years. There is, however, no waiting list for dying. No one blocks that. The testing costs 44.1x more than proven alternatives and excludes 86.1% of the patients who'll actually take it. For every 1 unit of harm prevented, the system creates 3.07k through denied access. Here's how to fix it.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/fda-is-unsafe-and-ineffective-og-retro-academic.jpg", "tags": [ "problem", "fda", "clinical-trials", "drug-approval", "bureaucracy", "regulatory-capture" ], "sections": [ "A Note on Blame", "\"But What About Safety?\"", "The 44.1x Inefficiency Tax", "The 8.2 years Efficacy Lag", "What the 1962 Efficacy Requirements Changed", "The Modern Consequences", "Off-Patent Drugs and Rare Diseases: Mathematically Doomed", "The Actual Death Toll of \"Drug Lag\"", "How the Incentives Work", "FDA Regulator Decision Tree", "The Math: Why Current Regulations Increase Total Harm", "Clinical Trial Theater: Excluding 86.1% of Reality Makes Drugs More Dangerous", "No Long-Term Outcome Data", "Pre-Specification Requirements Kill Innovation", "The Blinding Catch-22: How Knowing a Drug Works Proves It Doesn't", "Small Trials Are Dangerous", "The Negative Results Black Hole", "Countries That Don't Have Our \"Safety\"", "The COVID Test Fiasco", "The Bottom Line", "Technical Analysis" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/problem/unrepresentative-democracy.qmd", "url": "https://manual.WarOnDisease.org/problem/unrepresentative-democracy.html", "title": "Unrepresentative Democracy", "description": "Your government spends 604 times more on weapons than on testing which medicines work. You could elect 535 Gandhis and within two years they'd be funding nuclear weapons programs, because the system requires it. Princeton studied 1,779 of your policy decisions and found that public opinion has the same effect on legislation as a houseplant. This chapter explains why you can't vote your way out, and why that's actually fine, because the solution was never better politicians.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/unrepresentative-democracy-og-retro-academic.jpg", "tags": [ "democracy", "public-choice-theory", "voting", "collective-action", "incentives", "politics" ], "sections": [ "What Democracy Looks Like From Space", "The Mathematics of Why Nobody Fixes Anything", "Concentrated Benefits vs. Diffuse Costs", "The Death Spiral: How Two Choices Kill 330 Million Options", "How Money Buys Your Government", "The Lobbying ROI: Better Than Every Other Investment", "Your Congressman: A Professional Fundraiser Who Occasionally Dabbles in Legislation", "Congressional Committees: The Menu", "Public Choice Theory (Or: The Nobel Prize for Cynicism)", "What Each Institution Actually Optimizes For", "The Misdiagnosis", "Regulatory Capture: How the Burglar Trained the Guard Dog", "The Self-Sustaining War Machine", "The Ratchet", "The Equilibrium", "The Solution They Don't Want You to Have" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/central-banks.qmd", "url": "https://manual.WarOnDisease.org/economics/central-banks.html", "title": "Money Comes From a Building and They Use It to Kill People", "description": "Your money is manufactured in a building by people you didn't elect. It has funded unpopular wars that killed 97 million people. They give it to their friends first, then use the rest to buy weapons you didn't ask for. By the time it reaches you, it buys less. This has been happening for a century. Nobody covers it on the news because it is, by design, extremely boring.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/central-banks-og-retro-academic.jpg", "tags": [ "central-banking", "war-funding", "monetary-policy", "federal-reserve", "inflation" ], "sections": [ "The Pattern: Print, Kill, Repeat", "The Roman Empire (3rd Century)", "Revolutionary France (1790s)", "Weimar Germany (1920s)", "The American Money Printer", "The Receipt", "What About Wars Under Hard Money?", "1971: The Day Your Money Stopped Meaning Anything", "Why He Did It", "What He Killed", "What Actually Happened", "The Dual Mandate (Or: The Two Goals of Serfdom)", "Goal 1: \"Maximum Employment\" (Keep Everyone Busy)", "Goal 2: \"Stable Prices\" (Take 2% Per Year)", "The \"Deflation Is Dangerous\" Story", "The One Data Point", "The \"Banking Panics\" Defense", "What They Could Measure Instead", "How the Robbery Works", "The Spread", "The 2020 Demonstration", "The Theft That Followed", "The Two-Income Trap", "The Time They Broke It", "Your 93% Pay Cut (Measured in Shiny Rocks)", "Why Nobody Told You", "\"But It Wasn't the Gold Standard, It Was...\"", "Why You Don't Know Any of This", "Same Trick, Different Costume", "The Priesthood", "The Fake Nobel Prize", "The Research", "Why \"Just Print More Money for Medicine\" Doesn't Work", "The Fixed Pie of Human Genius", "The Shell Game (How Inflation Steals Medical Progress)", "The Proof: 50 Years of Going Nowhere", "\"Just Tax the Billionaires\"", "Why Money Printing Matters: Geniuses Follow the Money", "The Two Receipts", "Receipt 1: What the Printer Killed", "Receipt 2: What the Printer Wasted", "The Ask" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/problem/genetic-slavery.qmd", "url": "https://manual.WarOnDisease.org/problem/genetic-slavery.html", "title": "Genetic Slavery", "description": "Your government spends 604 more on weapons than on curing disease, and you think that's a political problem. It's not. It's a hardware problem. You're running 200,000-year-old software optimized for hoarding rocks and fearing strangers, and you've given it nuclear weapons. This chapter is the owner's manual for the brain that's trying to kill you.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/problem/genetic-slavery-og-retro-academic.jpg", "tags": [ "evolution", "psychology", "selfish-gene", "scarcity", "violence", "human-nature", "stupidity" ], "sections": [ "How Hydrogen Learned to Worry (A 13.8 Billion Year Recap)", "The Selfish Gene Made You Illogical (It Was a Good Idea at the Time)", "Part 1: Your Brain Was Optimized for a World That Doesn't Exist", "The Violence Module (Or: Why You Tend to Prefer Bombs Over Clinical Trials)", "The Tribal Brain (Or: Why Democracy Was Always Going to Be a Mess)", "The Compassion Gradient (Or: Why You'll Buy Your Cat a Birthday Cake While Children Starve)", "Your Brain Is a Museum of Obsolete Instincts", "Part 2: Genetic Slavery is Literally Killing You", "Part 3: Why You Can't Just \"Be Better\"", "Part 4: Breaking the Chains" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution.qmd", "url": "https://manual.WarOnDisease.org/solution.html", "title": "Optimization Summary", "description": "Optimized replacements for the systems identified in the failure analysis", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution-og-retro-academic.jpg", "tags": [ "solution", "1-percent-treaty", "dih", "dfda", "peace-dividend", "national-security", "victory-bonds" ], "sections": [ "A 1% Treaty", "Your Decentralized Institutes of Health", "Wishocracy", "Your Decentralized Framework for Drug Assessment", "Who Wins", "The Scaling Engine", "The War on Disease", "Why This Isn't Clinically Insane", "The Meta-Solution", "What Comes Next" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/1-percent-treaty.qmd", "url": "https://manual.WarOnDisease.org/solution/1-percent-treaty.html", "title": "A 1% Treaty", "description": "You have enough nuclear weapons to kill everyone 13 times. Here's how to settle for 12.87 times and use the savings on medicine. Controversial, apparently.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/1-percent-treaty-og-retro-academic.jpg", "tags": [ "solution", "1-percent-treaty", "dih", "peace-dividend", "national-security", "mutual-survival" ], "sections": [ "How It Works", "This Isn't a Trade-Off", "Why Your Most Expensive Things Are Also Your Most Useless Things (A Mystery)", "The Blueprint", "What Each Country Pays", "National Security (Which Is What You Call It When You Spend Money on Things That Don't Make You Secure)", "Real Threats (That Actually Kill People)", "Overfunded Threats (That Countries Spend Trillions On)", "The Rebranding Campaign: From \"Weakness\" to \"Strategic Genius\"", "\"The Strategic Health Defense Initiative\"", "The Talking Points That Make Hawks Sound Like Doves", "The Money Flow", "The 1% Treaty Fund", "Year One Projected Outcomes", "The Incentive Structure", "What Happens If This Actually Works", "The Endgame", "The Ratchet Effect", "Avoiding Treaty Pitfalls", "Reservation Games", "Ratification Delays", "Creative Accounting", "Parliamentary Obstacles", "Summary", "Addendum: The Actual Treaty Text (First Draft)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/dih.qmd", "url": "https://manual.WarOnDisease.org/solution/dih.html", "title": "Decentralized Institutes of Health", "description": "Your military-industrial complex solved coordination for killing: weapons manufacturers, generals, politicians, and factory workers all profit from the same budget, so they all show up. Disease has no such coalition. Your Decentralized Institutes of Health builds one. It does three things: receive treaty funds, allocate them via patient choice and wishocratic voting, and pay based on results instead of grant applications. It's SHAEF for the war on disease. Same selfishness as the military-industrial complex, but pointed at biology instead of each other. Nobody gets paid for writing essays about why they should be allowed to try curing things. They get paid for curing things.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/dih-og-retro-academic.jpg", "tags": [ "solution", "dih", "governance", "funding-model", "coordination" ], "sections": [ "The Health-Industrial Complex: Coordinating Your War on Disease", "The Olsonian Problem", "SHAEF for Your War on Disease", "The ROI Maximization Protocol", "Pay for Results (A Concept Your Research Sector Has Somehow Avoided)", "Your Data Commons: Publish Everything", "Governance: Sick People Choose, Everyone Else Votes", "Making Selfishness Cure Disease", "How Your Researchers Get Paid", "How It Works For Your Patients", "How the Money Flows", "The Architecture", "The Fund Flow", "What Gets Funded: Market Failures Only", "What Your Decentralized Institutes of Health Outsources (Everything)", "Anti-Capture Design", "Security: Defense in Depth", "What You've Just Read" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/wishocracy.qmd", "url": "https://manual.WarOnDisease.org/solution/wishocracy.html", "title": "Wishocracy", "description": "How to let billions of people say whether the next marginal public dollar should buy another nuclear weapon system or fund another pragmatic clinical trial, without routing the answer through lobbyists, committees, and middlemen.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/wishocracy-og-retro-academic.jpg", "tags": [ "solution", "wishocracy", "governance", "ai", "collective-intelligence", "resource-allocation", "democracy-but-working" ], "sections": [ "How Wishocracy Allocates High-Level Priorities", "What Wishocracy Actually Decides:", "How It Works: Pairwise Slider Allocation", "Why This Actually Works (Math Warning)", "\"But Direct Democracy Has Been Tried\" (Yes. Badly.)", "Your Current System Is Phone-a-Friend (But Your Friend Is Being Bribed)", "The 26-Point Gap Is a Floor, Not a Ceiling", "Why Markets Solved This (and Why You Still Need Wishocracy)", "From Priorities to Projects (Where Wishes Become Tasks)", "Why the Algorithm Is the Constitution", "Algorithmic Protections (Rules Nobody Can Break Because They're Not Rules)", "What Wishocracy Measures" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/dfda.qmd", "url": "https://manual.WarOnDisease.org/solution/dfda.html", "title": "A Decentralized FDA", "description": "On Wishonia, you type in what's wrong with you, see what worked for everyone else, and try it. The outcomes get recorded automatically. We've had this for millennia. Your decentralized FDA is the same thing, built with technology you already have. It's an open protocol that connects treatments to patients, records what actually happens, and publishes the results. Consumer Reports, but for not dying. It cuts trial costs from $41K to $929, expands capacity from 1.9 million patients/year to 23.4 million patients/year, and replaces your 40-page drug inserts with Outcome Labels that tell you what actually happened to real humans who took the pill.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/dfda-og-retro-academic.jpg", "tags": [ "overview", "dfda", "bureaucratic-murder", "death-by-clipboard" ], "sections": [ "The Solution: Consumer Reports for Drugs", "How It Works: Just Let People Try Stuff (Carefully)", "The Power of Real-World Evidence (Or: Spying on Sick People for a Good Cause)", "The Two-Stage Pipeline: Watch First, Then Test", "Proof It Works (While the FDA Wasn't Looking)", "The Oxford Recovery Trial: How the British Accidentally Saved Medicine", "What You'd See: FDA.gov 2.0", "Step 1: Type in What's Killing You", "Step 2: See What Actually Works (Based on Reality, Not Theory)", "Step 3: Join a Trial from Your Couch (While Dying Comfortably)", "Step 4: Get Drugs Delivered Like Pizza (But More Life-Saving)", "Step 5: Publish Results", "Step 6: Everyone Benefits from Everyone's Suffering", "Outcome Labels: Nutrition Facts for Drugs", "Your Personal Death-Prevention Assistant: The FDAi", "Making It Legal to Not Die", "The Business Model: How Everyone Profits Except Disease", "How Companies Register Treatments (5 Minutes, Zero Approval Needed)", "The Payment Flow", "Why This Creates Vastly More Research Capacity", "The Money Shot: How to Save 95% on Not Killing People", "The Itemized Receipt of Eliminated Stupidity", "The Partnership Approach: Building Rails, Not Trains", "The Players Already in the Game", "Federated, Not Centralized", "Why This Works: The Mathematical Impossibility of Committees", "The Future: Where Death Becomes Embarrassing", "2027: The Beginning of the End of Dying Slowly", "2030: Big Pharma Pivots or Dies", "2035: The Great Revelation", "2050: Death Becomes Opt-In", "How Your Decentralized FDA Actually Works" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/aligning-incentives.qmd", "url": "https://manual.WarOnDisease.org/solution/aligning-incentives.html", "title": "Aligning Incentives", "description": "Pharmaceutical companies make more money treating you forever than curing you once. Defense contractors earn $1,425 per lobbying dollar. Nobody is evil. The incentives are. Rearrange the profit motive so curing disease pays better than causing it, and watch capitalism accidentally save your species.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/aligning-incentives-og-retro-academic.jpg", "sections": [ "Defense Contractors: Teaching Merchants of Death to Love Life", "The Offer", "The Math", "Why They Take It", "What You're NOT Asking", "Why This Works", "The Timeline", "Insurance Companies: The Accidentally Aligned Industry", "Their Current Death Spiral", "Your Salvation Offer", "Why They're Your Natural Allies", "Pharmaceutical Companies: Converting Drug Dealers to Drug Curers", "Their Current Trap", "The Math That Converts Them", "Pharma's New Business Model: Volume Over Blockbusters", "How to Get Them Onboard", "Politicians: Hacking Democracy's Source Code", "Their Current Misery", "Your Political Welfare Program", "The Bipartisan Beauty", "Billionaires: Self-Interest Meets Self-Preservation", "The Domino Effect", "Why This Can Work: The Coordination Problem Has a Price Tag", "Why This Scales: The Ratchet Effect" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/incentive-alignment-bonds.qmd", "url": "https://manual.WarOnDisease.org/solution/incentive-alignment-bonds.html", "title": "Incentive Alignment Bonds", "description": "War bonds, but backwards. Your grandparents funded WW2 at roughly 3% returns. You fund disease eradication at 272%. Same structure, fewer Nazis, better spreadsheet.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/incentive-alignment-bonds-og-retro-academic.jpg", "tags": [ "financial-instruments", "mechanism-design", "governance-innovation", "economics", "fundraising", "bond-structure", "campaign-finance", "capital-raising" ], "sections": [ "The Core Problem: Good Ideas Die in Committee", "How IABs Work (Four Steps)", "The Three-Layer Architecture (How to Not Go to Prison)", "Worked Example: How Senator Smith Votes Yes", "The Revenue Split", "Why 10% Goes to Political Incentives", "Beyond the 1% Treaty", "For Investors", "The Investor Pitch", "The Perpetuity Math", "Security Package and Risk", "How It Compares (If It Works)", "Investment Thresholds and Term Sheet", "Summary" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/solution/optimocracy.qmd", "url": "https://manual.WarOnDisease.org/solution/optimocracy.html", "title": "Optimocracy: The Evidence Machine", "description": "On Wishonia, the Optimitron comes free with your first government. Its Optimal Budget Generator (OBG) and Optimal Policy Generator (OPG) check which policies work by looking at the 10,000 places that already tried them. Your species skipped this step and went straight to arguing.", "image": "https://manual.WarOnDisease.org/assets/images/optimocracy-paper/optimocracy-paper-section-the-mechanism-bw-academic.jpg", "tags": [ "solution", "optimocracy", "governance", "causal-inference", "evidence-based-policy", "capture-resistance" ], "sections": [ "The Only Two Numbers That Matter", "The Price of Not Checking", "The Answer Key You Already Have", "Why Knowing Isn't Enough", "The Mechanism: Recommend, Track, Reward", "Corruption, But Make It Difficult", "Putting It Together" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/appendix/open-ecosystem-and-bounty-model.qmd", "url": "https://manual.WarOnDisease.org/appendix/open-ecosystem-and-bounty-model.html", "title": "How to Not Build Most of It", "description": "A dFDA strategy for getting other people to build everything through open APIs and bounties, like WordPress but for not dying.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/open-ecosystem-and-bounty-model-og-retro-academic.jpg", "tags": [ "strategy", "open-source", "bounties", "platform-economics", "ai-development" ], "sections": [ "The Open Platform Model", "Bounties: Paying for Results, Not Promises", "This Already Works" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/proof.qmd", "url": "https://manual.WarOnDisease.org/proof.html", "title": "The Proof: Overview", "description": "This Already Works - Pragmatic trials prove 44.1x efficiency. History proves every component. Switzerland, war bonds, landmines, the 3.5% rule, and Wall Street's craziest bets all prove humans can accidentally do smart things when properly motivated.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/proof-og-bw-academic.jpg", "tags": [ "evidence", "proof", "pragmatic-trials", "recovery-trial", "switzerland", "peace-dividend", "3-5-rule", "war-bonds", "precedents", "history", "social-movements", "finance", "governance" ], "sections": [ "Pragmatic Trials: 44.1x More Efficient", "Humans Doing Smart Things (Accidentally): A Collection", "That Time Humans Banned Landmines (Yes, Really)", "War Bonds: That Time Grandma Funded WW2", "The Global Fund (Proof That New Health Institutions Can Exist)", "Post-WW2: That Time America Accidentally Discovered Peace Is Profitable", "The 1990s: When the Berlin Wall Fell and Wallets Exploded", "Switzerland: 200 Years of Not Shooting Anyone = Being Very Rich", "The 3.5% Rule: The Cheat Code for Democracy", "You Have Advantages They Didn't", "When Good Intentions Met Reality (And Lost)", "Eisenhower's Warning: A 5-Star General Tried to Tell You", "The Nuclear Freeze Movement: Millions of People, Zero Results", "Occupy Wall Street: When \"We're Angry\" Isn't a Strategy", "On How Rich People Made Money Doing Crazy Things (And Why That Matters)", "On The Time Junk Bonds Saved Capitalism", "On The Time George Soros Broke England", "On When Smart People Lost All Their Money (The Cautionary Tales)", "The Ultimate Failsafe: The Worst-Case Scenario is Still a Win", "How Your Decentralized FDA Would Compare to History's Best Health Interventions" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/proof/body-as-repairable-machine.qmd", "url": "https://manual.WarOnDisease.org/proof/body-as-repairable-machine.html", "title": "You Are a Meat Robot", "description": "The usual objection to curing all disease is that it's impossible. You replace 330 billion cells a day. You 3D-print windpipes. You reprogram skin into brain cells. You've already proven your body is a machine, and machines are repairable. The only reason you haven't repaired it is that you spent the repair budget on missiles. This chapter removes the \"impossible\" objection so you can get back to the \"expensive\" objection, which the treaty solves.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/proof/body-as-repairable-machine-og-retro-academic.jpg", "tags": [ "biology", "aging", "regenerative-medicine", "repair", "engineering", "proof", "car-analogy" ], "sections": [ "Death is a Technical Problem", "You Are a Self-Repairing Meat Robot", "You've Already Started Fixing the Machine", "Exhibit A: You Can Grow New Parts", "Exhibit B: You Can Reprogram Your Cells", "Exhibit C: You're Debugging Your Code", "The Car Restoration Analogy", "The Proof That Aging is Reversible", "Nature Already Does It", "You've Already Reversed Aging (In Mice... and Human Cells)" ], "published": true, "lastmod": "2026-03-07" }, { "path": "knowledge/proof/why-hasnt-anyone-done-this.qmd", "url": "https://manual.WarOnDisease.org/proof/why-hasnt-anyone-done-this.html", "title": "Why Hasn't Anyone Done This?", "description": "People have. Many times. Sachs, the WHO, the Copenhagen Consensus, Nobel laureates. They all stalled for the same reason: no self-sustaining financial mechanism. The math was never the missing piece. The engine was.", "tags": [ "proof", "meta-objection", "predecessors", "funding-mechanisms", "dysfunction-tax", "compound-effect" ], "sections": [ "People Have Tried This", "Every Previous Attempt Had the Same Problem", "The Combination Falls Between Every Institution's Brand", "The Compound Math Is the Hard Part (Honestly)", "Why This Time Might Be Different" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/futures.qmd", "url": "https://manual.WarOnDisease.org/futures.html", "title": "The Two Futures", "description": "Two timelines diverge from this moment. One ends in extinction, the other in transcendence. The only difference is a 1% budget reallocation.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/futures-og-retro-academic.jpg", "tags": [ "futures", "dystopia", "utopia", "moronia", "wishonia", "three-supers", "three-subs" ], "sections": [ "Path A: Moronia", "Path B: Wishonia", "The Only Variable" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/futures/moronia.qmd", "url": "https://manual.WarOnDisease.org/futures/moronia.html", "title": "The Cautionary Tale of Moronia", "description": "A planet had every tool needed to cure disease and chose to build weapons instead. They went extinct. Their last words were 'but the economy.' This is a bedtime story for civilizations that can't do math.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/futures/moronia-og-retro-academic.jpg", "tags": [ "dystopia", "moronia", "ai-weapons", "collapse" ], "sections": [ "The Discovery", "What I Tried to Tell Them", "The Cascade", "Year Zero: Already Broken (Much Like You)", "The Spiral (Already in Progress)", "The Warehouses", "The Ratchet", "Years 1-5: The Acceleration", "The Weapons Speak", "The Logic Trap", "Everything Dies", "The Mirror" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/futures/wishonia.qmd", "url": "https://manual.WarOnDisease.org/futures/wishonia.html", "title": "Wishonia", "description": "On one planet, citizens allocate the budget directly, lobbyists don't exist, and disease was eradicated 4,000 years ago. It uses the same technology you have. The difference is they pointed it at biology instead of each other.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/futures/wishonia-og-retro-academic.jpg", "tags": [ "utopia", "future", "peace-dividend", "post-scarcity", "health", "happiness" ], "sections": [ "What the Optimized World Looks Like", "Biology Becomes Software", "A Day in the Optimized Life", "The Diseases That Stopped Existing", "The Peace Dividend Economy", "Your Corporate Heroes", "Our Current Problems", "What Fixing Health Fixed", "Climate", "Poverty", "Science", "Peace and Governance", "Happiness", "Freedom", "The Three Supers Complete", "Your Personal Future", "What Comes After", "Your Two Paths" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/faq.qmd", "url": "https://manual.WarOnDisease.org/appendix/faq.html", "title": "Frequently Asked Objections", "description": "Fun facts for those reasonably skeptical of spending 1% more on helping sick people than killing them.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/faq-og-retro-academic.jpg", "sections": [ "\"We Need the Military Budget\"", "\"Big Pharma Will Block This\"", "\"What About National Sovereignty?\"", "\"The FDA Exists for a Reason\"", "\"What If Countries Cheat?\"", "\"You Can't Cure Aging\"", "\"I'm Just One Person\"", "\"Why Not Just Reform the System?\"", "\"This Is Politically Impossible\"", "\"What If the Science Is Wrong?\"", "\"War Is Human Nature\"", "\"All Wars on X Have Failed\"", "\"This Sounds Like Bribery\"", "\"Why Not Just Use Philanthropy?\"", "\"84 Quadrillion Dollars Is a Made-Up Number\"", "\"How Do You Prevent Waste?\"" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/strategy/roadmap.qmd", "url": "https://manual.WarOnDisease.org/strategy/roadmap.html", "title": "The Roadmap to End War and Disease", "description": "This isn't a protest. It's a recipe. Step one, collect papers from rich humans (using greed). Step two, get 280 million humans to click a button (using paid referral bonuses, because your species won't save itself for free). Step three, apply papers to politicians until the treaty happens (using the only language they understand). Every step has a budget, a timeline, and a contingency plan for the fact that you're you.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/roadmap-og-retro-academic.jpg", "tags": [ "roadmap", "strategy", "timeline", "execution-plan", "finance", "operations", "nonprofit", "victory-bonds", "referendum", "lobbying" ], "sections": [ "High-Level Strategy: The Three-Step Recipe for Not Dying", "Step 1: Collect Papers from Rich People", "Step 2: Tell Humans the Referendum Exists", "Step 3: Apply Papers to Politicians Until Treaty Happens", "The Sacred (Legal) Bribery Sequence", "(Legal) Bribe Category #1: Rich People (The Paper Collectors)", "(Legal) Bribe Category #2: The True Believers (Early Adopters)", "(Legal) Bribe Category #3: Regular People (Everyone Else)", "(Legal) Bribe Category #4: Politicians (The Elected Paper Recipients)", "The Success Spiral", "The Timeline: From $0 to Ending Death", "The Legal Architecture: How to Be a Charity, a Lobbying Group, and a Hedge Fund Simultaneously", "Phase 4+: The Expansion Phases (Years 4-50)", "Why Expansion Is Built Into The System", "Here's Why It Keeps Growing", "The Endgame" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/strategy/nonprofit-coalition-strategy.qmd", "url": "https://manual.WarOnDisease.org/strategy/nonprofit-coalition-strategy.html", "title": "Why Every Nonprofit Should Support a 1% treaty", "description": "Nonprofits fighting disease currently compete for the same shrinking pile of donor money. A 1% treaty creates $27.2 billion in new funding. Every charitable organization can stop fighting over crumbs and start fighting for the bakery, if someone tells them the bakery exists.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/nonprofit-coalition-strategy-og-retro-academic.jpg", "tags": [ "strategy", "nonprofits", "coalition", "resource-allocation", "1-percent-treaty", "game-theory" ], "sections": [ "Why the Banquet Exists and Nobody Has Noticed", "\"But Shouldn't Nonprofits Focus on Their Core Mission?\"", "The Obvious Solution That Nobody Sees", "Why Your Species Only Changes When the Building Is On Fire", "The Factory Precedent", "\"Why Not Just Run Trials Without the Treaty?\"", "What 1% Less Violence Buys Every Mission", "On Bribing Nonprofits (Legally)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/legal/legal-framework.qmd", "url": "https://manual.WarOnDisease.org/legal/legal-framework.html", "title": "Legal Architecture", "description": "Bribing politicians is illegal unless you call it 'lobbying' or 'campaign contributions.' Then it's protected speech. Here's the legal architecture for saving humanity using your own ridiculous laws.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/legal/legal-framework-og-retro-academic.jpg", "tags": [ "legal-framework", "compliance", "securities-law", "election-law", "multi-jurisdiction", "organizational-structure" ], "sections": [ "Entity #1: Your 501(c)(3) Public Charity (\"The Brain\")", "Entity #2: Your 501(c)(4) Social Welfare Org (\"The Sword\")", "Entity #3: The Victory Corporation (\"The Engine\")", "Entity #4: Your Decentralized Institutes of Health Foundation (\"The Soul\")", "Why One Organization Pretending to Be Four", "The General Staff", "Securities Law (A Section Named After Oranges)", "Election Law (A Section About Legal Bribery)", "Treaty Framework", "Risk Mitigation (When They Come For You)" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/legal/election-law.qmd", "url": "https://manual.WarOnDisease.org/legal/election-law.html", "title": "Election Law", "description": "How to Buy Politicians Legally", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/legal/election-law-og-retro-academic.jpg", "sections": [ "The Legal Landscape: Money Is Speech", "Citizens United Changed Everything", "The Super PAC Strategy", "Setting Up \"Cure Not Kill PAC\"", "The 501(c)(4) Dark Money Machine", "Your Action Fund (The Dark Money Vehicle)", "Campaign Finance Jujitsu", "Making Opposition Expensive", "State and Local Compliance", "The Nightmare States", "The Compliance Strategy", "Local Elections", "The Media Buy Strategy", "Surgical Strikes", "The Ground Game", "Paid \"Volunteers\"", "The Petition Army", "Enforcement: What Happens If You Break Rules", "FEC Enforcement (LOL)", "DOJ Enforcement (Rare but Real)", "State Enforcement (Varies)", "The Lobbying Registration Trap", "When You Must Register", "When You Don't", "International Considerations", "Foreign Nationals Ban", "Treaty Promotion", "The Victory Conditions", "Phase 1: Create Fear (Months 1-6)", "Phase 2: Offer Carrots (Months 7-12)", "Phase 3: Ensure Victory (Months 13-18)", "Conclusion: Democracy as Designed", "Legal Notice" ], "published": true, "lastmod": "2026-03-06" }, { "path": "knowledge/strategy/legislation-package.qmd", "url": "https://manual.WarOnDisease.org/strategy/legislation-package.html", "title": "The Legislation Package", "description": "How to Write Laws That Actually Pass", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/legislation-package-og-retro-academic.jpg", "sections": [ "The Treaty Implementation Act: Making It Real", "The Core Provisions", "Why Politicians Will Vote Yes", "The Legislative Hack", "The Authorization Act for your Decentralized Institutes of Health: Creating Your Machine", "The Structure Designed to Resist Capture", "The Trojan Horse Approach", "The Poison Pills for Opposition", "The Parallel Track Act: Your Regulatory Revolution", "The Legal Architecture", "How to Sell This to Cowards", "The Implementation Trick", "The Right to Try Expansion Act: Medical Freedom", "The Provisions That Matter", "The Emotional Blackmail Strategy", "The Coalition Building", "The Budget Reallocation Act: Moving the Money", "The Money Flow Mechanics", "Making It Robust", "The Incremental Implementation", "The Legislative Strategy: Order of Operations", "Phase 1: Build Momentum", "Phase 2: Create Infrastructure", "Phase 3: Fund the System", "The Omnibus Strategy", "Conclusion: Democracy Theater at Its Finest" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/strategy/global-referendum.qmd", "url": "https://manual.WarOnDisease.org/strategy/global-referendum.html", "title": "Global Referendum Strategy", "description": "Humanity downloaded TikTok over 4 billion times to watch strangers twerk. Getting 280 million people to click 'yes' on not dying should be easier. Here's how, with math.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/strategy/global-referendum-og-retro-academic.jpg", "tags": [ "referendum", "governance", "identity", "verifiability", "privacy", "security", "viral-marketing", "fraud-prevention" ], "sections": [ "What You're Actually Building", "The Goal", "The Voting System", "On Stopping People from Cheating", "Growth Strategy", "Integrity (Proving You Didn't Cheat)", "Implementation Roadmap", "Success Metrics", "On Why 3.5% Is The Magic Number", "The Bottom Line" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/solution/ai-coordination-army.qmd", "url": "https://manual.WarOnDisease.org/solution/ai-coordination-army.html", "title": "Building Your AI Coordination Army", "description": "How to build and deploy autonomous AI agents that coordinate millions of people fighting the War on Disease.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/ai-coordination-army-og-retro-academic.jpg", "sections": [ "Where Your Agents Get Their Missions (Not From a Management Consultant)", "The Secret to Success: Cross-Sector Coordination (Forces for Good)", "Why You Need This (Humans Are Hilariously Bad at Coordination)", "The Architecture You're Building (It's Simpler Than It Looks)", "Step 1: Deploy Your Coordination Hub (Your Organization's Digital Slave Labor)", "To Mobilize Support", "To Accelerate Research", "To Build Awareness", "To Optimize Impact", "Step 2: Define Each Agent's Mission (From the Task Tree, Not From Your Feelings)", "Step 3: Enable Competition Between Agents (May the Best Robot Win)", "How You Keep Control (Preventing the Robot Uprising)", "AI Proposes", "You Decide", "AI Implements", "You Verify", "How You Prevent Data Silos (The Tragedy of the Nonprofit Commons)", "Rule 1 - Share to Play" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/appendix/treaty-feasibility.qmd", "url": "https://manual.WarOnDisease.org/appendix/treaty-feasibility.html", "title": "Treaty Feasibility & Cost Analysis", "description": "Previous treaties failed because they ran on guilt. Guilt has terrible fuel efficiency. This one runs on greed, which is (regrettably) humanity's only reliable fuel source.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/treaty-feasibility-og-retro-academic.jpg", "tags": [ "treaty", "diplomacy", "cost-analysis", "feasibility", "history" ], "sections": [ "What Treaties Actually Cost", "Inflation-Adjusted to 2024 Dollars", "Cost for a 1% Health Treaty", "The Math", "How to Make Governments Sign Things", "Timeline to \"Governments Can't Ignore This\"", "Political Success Probability: Economic Analysis", "Historical Precedents (The Depressing Table)", "Why a 1% Treaty is Harder Than Most Precedents", "Why a 1% Treaty Might Beat the Odds", "Probability Estimates", "Expected Value (Even When You Assume Failure)", "The Chain Reaction Model: Why This Idea Cannot Stay Contained", "Direct Encounters", "The Mathematics", "The Decision-Theoretic Case: Why Rational Actors Eventually Move", "The Incentive Structure", "Why the EV Is Not Just Moral", "Why This Should Matter Even to a Self-Interested Billionaire", "Conditional Near-Inevitability Claim", "Minimal Launch Probability Model", "Why Delay Becomes Irrational", "What Would Have To Be Wrong", "Why This Still Feels Inevitable", "Why The Treaty Won't Stop at 1%", "The Expansion Mechanism", "Why This Differs from Every Other Treaty", "The Ratchet Effect", "Long-Term Feasibility" ], "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/appendix/recruitment-and-propaganda-plan.qmd", "url": "https://manual.WarOnDisease.org/appendix/recruitment-and-propaganda-plan.html", "title": "Recruitment & Propaganda Plan", "description": "You want to end war and disease but don't have a nonprofit, a bank account, or anything to offer anyone. Here's how to recruit 100,000 humans before you have anything except an argument. It's a Kickstarter where the reward tier is 'possibly not dying,' which is the most compelling crowdfunding offer in history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/recruitment-and-propaganda-plan-og-retro-academic.jpg", "tags": [ "operations", "fundraising", "recruitment", "strategy", "propaganda" ], "sections": [ "The Bureaucratic Nesting Doll Problem", "Three Types of Humans Who Want to Help", "Spreadsheet Humans (Investors)", "Heart Humans (Advocates)", "Institutional Humans (Partners)", "Phase 0: The Shopping List", "Getting Started (It Takes Twenty Minutes)", "The Comforting Asymmetry", "The Question You Can't Answer Wrong", "The Zero Percent Problem", "How Trivial, Exactly", "The Only Remaining Failure Mode", "Your Ammunition (Copy, Paste, Send)", "The Message", "Variations", "Which Message for Which Human" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/conclusion.qmd", "url": "https://manual.WarOnDisease.org/appendix/conclusion.html", "title": "Conclusion", "published": true, "lastmod": "2026-03-09" }, { "path": "knowledge/economics/peace-dividend.qmd", "url": "https://manual.WarOnDisease.org/economics/peace-dividend.html", "title": "Peace Dividend", "description": "Your government spends more on camouflage paint than on curing Alzheimer's. Move 1% of the bomb budget to medicine: $27.2 billion for clinical trials, plus $114 billion saved by slightly fewer explosions. The worst-case scenario is still the largest increase in medical research in history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/peace-dividend-og-retro-academic.jpg", "tags": [ "peace-dividend", "1-percent-treaty", "economic-analysis", "cost-of-war" ], "sections": [ "How 1% Less Violence Pays For Everything", "The Captured Money: $27.2B/Year", "The Bonus Savings: $114B/Year", "Where the $114B Comes From", "The Two Numbers", "The Elasticity Question", "The Part Where the Math Gets Embarrassing", "What You're Assuming (and Where It Gets Shaky)", "The GDP Multiplier", "The Elasticity Assumption", "How Good Are the Sources?", "The Safe Bet", "The Trajectory, Not the Snapshot", "Two Futures" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/gdp-trajectories.qmd", "url": "https://manual.WarOnDisease.org/economics/gdp-trajectories.html", "title": "Two Paths: GDP Trajectories", "description": "Your economists project 2.5% annual growth. This requires 20 consecutive years of nothing going wrong, which your species has never achieved. Meanwhile your destructive economy (military spending plus its cybercrime offspring) is already 11.5% of GDP and growing faster than your actual economy. The Soviet Union collapsed at 15-18%. This chapter models two paths, the one you're on and the one where you redirect the murder budget. One ends with average income at $339K. The other ends with cockroaches finding this manual.", "tags": [ "gdp-trajectories", "economic-analysis", "peace-dividend", "expected-value", "current-trajectory", "wishonia", "cybercrime", "military-spending" ], "sections": [ "Two Paths", "Your Current Trajectory", "So How Long Do You Have?", "You Already Know What This Looks Like", "What We Did Instead", "The Decision", "What This Means Per Person", "Go Ahead, Change the Numbers" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/economics/health-dividend.qmd", "url": "https://manual.WarOnDisease.org/economics/health-dividend.html", "title": "Health Dividend", "description": "6.65 thousand diseases have zero approved treatments. At your current pace, you'll get to all of them in 443 years. Redirect 1% of military spending and it drops to 36 years, preventing 10.7 billion deaths at 50.3kx the cost-effectiveness of anti-malaria bed nets. The whole thing costs less per year to run than Halloween costumes for dogs. But sure, take your time.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/health-dividend-og-retro-academic.jpg", "tags": [ "dfda", "roi", "clinical-trials", "cost-reduction", "economics" ], "sections": [ "From Explosions to Trial Slots", "The Waiting List", "The Body Count", "The Price Tag on Not Being Dead", "The Receipt" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/economics/financial-plan.qmd", "url": "https://manual.WarOnDisease.org/economics/financial-plan.html", "title": "Financial Plan", "description": "Most financial plans are complicated because the writers are confused or lying. This one has three steps. Raise $1B (using greed, not generosity, because greed is faster). Spend it to pass the treaty. Manage $27.2B a year forever, with 80% curing diseases, 10% paying investors, and 10% keeping politicians obedient. The corruption is capped at 20% and fully transparent, which already makes it the most honest government program in your country's history.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/financial-plan-og-retro-academic.jpg", "tags": [ "finance", "overview", "strategy", "treasury-management" ], "sections": [ "Pillar 1: The Money Part (Raise $1B)", "Pillar 2: The Spending Part (Spend $1B)", "The Part That Makes It Cheap", "Pillar 3: The Forever Part (Manage $27.2B+/Year)", "How the Money Gets Spent: 80/10/10", "Dynamic Patient Subsidies", "The Whole Thing on One Line" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/economics/campaign-budget.qmd", "url": "https://manual.WarOnDisease.org/economics/campaign-budget.html", "title": "Campaign Budget: The $1B Legal Bribery Machine", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/economics/campaign-budget-og-retro-academic.jpg", "sections": [ "Why $1B Instead of $5B", "The Minimum Viable Budget", "Where the Papers Go", "Viral Referendum (part of $250M Referendum Budget)", "Professional (Legal) Bribery (part of $650M Lobbying Budget)", "Technology (part of $250M Referendum Budget)", "Lawyers (AI-Assisted) (part of $650M Lobbying Budget)", "Co-opting the Opposition (part of $650M Lobbying Budget)", "Operations (overhead across all categories)", "Post-Victory Transition: $100M", "Timeline", "Why This Works", "Returns", "Transparency", "Adaptive Management", "Summary" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/appendix/investor-risk-analysis.qmd", "url": "https://manual.WarOnDisease.org/appendix/investor-risk-analysis.html", "title": "Investor Risk Analysis", "description": "VICTORY Incentive Alignment Bonds vs. Traditional Venture Capital - Analysis of the unique risk profile of a 1% treaty initiative, comparing its political arbitrage model to the market-risk model of venture capital.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/investor-risk-analysis-og-retro-academic.jpg", "tags": [ "risk-analysis", "investment-thesis", "venture-capital", "political-arbitrage", "assurance-contracts", "metaculus" ], "sections": [ "Political Arbitrage vs. Venture Capital", "Risk Comparison", "How You Mitigate Each Risk", "The Assurance Contract (Fundraising Risk)", "Prediction Markets & Dynamic Pricing (Political Risk)", "Front-Loaded Payouts (Timeline Risk)", "First-Loss Capital (Financial Risk)", "Conclusion: Is This Less Risky Than VC?" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://manual.WarOnDisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/appendix/recovery-trial.qmd", "url": "https://manual.WarOnDisease.org/appendix/recovery-trial.html", "title": "The Oxford RECOVERY Trial", "description": "Proof that decentralized pragmatic trials reduce costs by 82X while saving millions of lives", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/recovery-trial-og-retro-academic.jpg", "tags": [ "clinical-trials", "cost-efficiency", "recovery-trial", "historical-proof", "oxford" ], "sections": [ "Pragmatic vs Traditional Trials", "Key RECOVERY Trial Statistics", "They Used Regular Hospitals", "They Collected Only Useful Data", "They Integrated With Normal Care", "They Were Flexible", "They Prioritized Speed Over Bureaucracy", "The Result", "What RECOVERY Proved", "Cost Per Medical Answer", "Sources", "Scaling RECOVERY's Model" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/appendix/real-world-evidence-historical-success.qmd", "url": "https://manual.WarOnDisease.org/appendix/real-world-evidence-historical-success.html", "title": "Real-World Evidence Historical Success (Pre-1962)", "description": "How decentralized physician trials from 1883-1962 achieved 4 years/decade life expectancy gains, and what happened when the 1962 regulations replaced them with industry-controlled trials", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/appendix/real-world-evidence-historical-success-og-retro-academic.jpg", "tags": [ "appendix", "historical-evidence", "real-world-evidence", "fda", "clinical-trials", "life-expectancy", "1962-regulations" ], "sections": [ "Historical Evidence: Why Real-World Evidence Works Better", "10,000 Years of Dying at 30", "1883 – The Year You Figured It Out", "The Result", "1938 – The FDA Requires Phase 1 Safety Trials", "1950s – Thalidomide: When Safety Regulations Actually Worked", "1962 – The Year You Decided to Make Everything Worse", "What Happened to Life Expectancy (The Part That Matters)", "The \"Diminishing Returns\" Excuse", "The \"Correlation Is Not Causation\" Excuse", "Impact of Innovative Medicines on Life Expectancy", "The Summary" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/papers.qmd", "url": "https://manual.WarOnDisease.org/papers.html", "title": "Papers & Publications", "description": "Academic papers and working drafts from the Disease Eradication Plan project.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/papers-og-bw-academic.jpg", "sections": [ "The 1% Treaty: Harnessing Greed to Eradicate Disease", "Ubiquitous Pragmatic Trial Impact Analysis: How to Prevent a Year of Death and Suffering for 84 Cents", "Incentive Alignment Bonds: Making Public Goods Financially and Politically Profitable", "Wishocracy: Solving the Democratic Principal-Agent Problem Through Pairwise Preference Aggregation", "The Political Dysfunction Tax", "The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag", "The Price of Political Change: A Cost-Benefit Framework for Policy Incentivization", "United States Efficiency Audit", "Optimocracy: Causal Inference on Cross-Jurisdictional Policy Data to Maximize Median Health and Wealth", "The Optimal Policy Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Policy", "The Optimal Budget Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Goods Funding", "The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials)", "Right to Trial & FDA Upgrade Act", "How to End War and Disease", "Drug Development Cost Increase Analysis" ], "published": true, "lastmod": "2026-03-10" }, { "path": "knowledge/references.qmd", "url": "https://manual.WarOnDisease.org/references.html", "title": "Source Quotes and References", "description": "Every claim in this manual has a receipt. 347 sources, because 'trust me, I'm an alien' is not a citation format your species recognizes.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/references-og-bw-academic.jpg", "tags": [ "references" ], "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/appendix/copyright.qmd", "url": "https://manual.WarOnDisease.org/appendix/copyright.html", "title": "Copyright", "published": true, "lastmod": "2026-03-03" }, { "path": "knowledge/appendix/back-cover.qmd", "url": "https://manual.WarOnDisease.org/appendix/back-cover.html", "title": "About This Manual", "description": "The complete idiot's guide to legally bribing your way to utopia.", "image": "https://manual.WarOnDisease.org/assets/og-images/knowledge/solution/1-percent-treaty-og-retro-academic.jpg", "sections": [ "Storefront Descriptions", "The Gradual Irrationality Reduction Program", "Reviews & Awards (pick one or mix)", "Author Biography", "Translator Biography", "Keywords", "Categories", "BISAC Codes" ], "published": true, "lastmod": "2026-03-09" } ], "pageCount": 50 }, { "id": "obg", "type": "website", "title": "The Optimal Budget Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Goods Funding", "description": "The Optimal Budget Generator (OBG) uses causal inference, diminishing returns modeling, and cost-effectiveness evidence to determine optimal public goods funding levels that maximize two welfare metrics: real after-tax median income growth and median healthy life years. For each spending category, OBG estimates an Optimal Spending Level (OSL) and produces a gap analysis showing where current government budgets are over- or underfunded relative to evidence-based benchmarks. The Budget Impact Score (BIS) measures confidence in each recommendation based on the quality of causal evidence.", "siteUrl": "https://obg.warondisease.org", "favicon": "https://obg.warondisease.org/assets/icons/dih-favicon.png", "ogImage": "https://obg.warondisease.org/assets/og/obg-og-1200x630.jpg", "pdfUrl": "https://obg.warondisease.org/obg-framework-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18356209", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Budget Optimization, Evidence-Based Policy, Cost-Effectiveness, Public Finance, Welfare Economics", "category": "Academic Paper, Public Policy, Economics", "keywords": [ "budget-optimization", "optimal-budget-generator", "evidence-based-policy", "meta-analysis", "cost-effectiveness", "diminishing-returns", "reference-country-benchmarking", "budget-impact-score", "welfare-economics", "public-finance" ], "audience": "Researchers, Policy Makers, Economists, Public Finance Specialists", "format": "Working Paper", "genre": "Economics, Public Policy, Evidence-Based Governance", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "123f44a0-d5b6-4ff3-9375-1f7e47fca053", "cname": "obg-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/optimal-budget-generator-spec.qmd", "outputDir": "_site/obg", "publishing": { "ownSite": { "url": "https://obg.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522044", "doi": "10.5281/zenodo.18356209" }, { "platform": "ssrn", "status": "pending", "url": "" } ], "journals": [ { "name": "Journal of Public Economics", "tier": 1, "status": "target", "url": "" }, { "name": "Journal of Policy Analysis and Management", "tier": 2, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/optimal-budget-generator-spec.qmd", "url": "https://obg.warondisease.org/appendix/optimal-budget-generator-spec.html", "title": "The Optimal Budget Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Goods Funding", "description": "The Optimal Budget Generator (OBG) uses causal inference, diminishing returns modeling, and cost-effectiveness evidence to determine optimal public goods funding levels that maximize two welfare metrics: real after-tax median income growth and median healthy life years. For each spending category, OBG estimates an Optimal Spending Level (OSL) and produces a gap analysis showing where current government budgets are over- or underfunded relative to evidence-based benchmarks. The Budget Impact Score (BIS) measures confidence in each recommendation based on the quality of causal evidence.", "image": "https://obg.warondisease.org/assets/og-images/knowledge/appendix/optimal-budget-generator-spec-og-bw-academic.jpg", "sections": [ "Abstract", "System Overview", "What Policymakers See", "Illustrative Example: US Federal Budget Gap Analysis", "What Budget Analysts See", "Where This Fits", "Implementation Mechanism", "Introduction", "Why Budget Allocation Fails Today", "The RDA Analogy: Optimal Levels, Not Just Marginal Returns", "What This Framework Provides", "Outcome Metrics: What We're Optimizing", "Related Work", "Budget Analysis Frameworks", "Evidence-Based Policy Movement", "Comparative Public Finance", "How OBG Differs", "Theoretical Framework", "The Social Planner's Problem", "Optimal Spending Levels Under Uncertainty", "Budget Impact Score as Precision Weighting", "Gap Analysis and Welfare Gains", "Welfare Bounds Under Model Uncertainty", "Summary of Theoretical Results", "Core Methodology", "Spending Category Data Structure", "Two Methods for OSL Estimation", "Diminishing Returns Modeling", "The Core Concept", "Finding the \"Knee\" of the Curve", "Estimation Methods", "Worked Example: K-12 Education Spending", "Worked Example: Pragmatic Clinical Trials", "The Highest-Return Public Investment", "OSL Estimation", "Diminishing Returns Analysis", "Cost-Effectiveness Calculation", "Gap Analysis", "Why This Category Dominates", "Cost-Effectiveness Threshold Analysis", "The Standard Health Economics Approach", "Building Up from Intervention-Level Data", "Worked Example: Vaccinations", "Budget Impact Score (BIS)", "BIS Calculation", "Evidence Grading from BIS", "Gap Analysis and Priority Ranking", "Computing Gaps", "Priority Score", "Illustrative Example: Priority Ranking", "Multi-Unit Reporting", "The Problem with Abstract Scores", "Reporting at Multiple Levels", "Conversion Factors", "Worked Example: Multi-Unit Output", "Quality Requirements and Validation", "Minimum Thresholds for OBG Estimation", "Robustness Checks", "Interpreting Results", "Gap Ranges and Recommended Actions", "What the Algorithm Cannot Tell You", "Pilot Program Prioritization", "Value of Information for Uncertain Categories", "Recommended Pilot Designs", "Learning Feedback Loop", "Data Sources", "Cross-Country Databases", "Cost-Effectiveness Databases", "US Budget Data", "Limitations", "Diminishing Returns Uncertainty", "Implementation Capacity", "Validation Framework", "Retrospective Validation", "Prospective Validation", "Success Metrics", "Validation Status", "Sensitivity Analysis", "Parameter Sensitivity", "Scenario Analysis", "Conclusion", "Acknowledgments", "References", "Appendix A: Analysis Workflow", "Complete OBG Analysis Pipeline", "Appendix B: Glossary", "Core Concepts", "Estimation Methods", "Evidence Quality", "Output Concepts", "Appendix C: Illustrative Comparison to US Budget", "Illustrative US Discretionary Budget vs. OSL Targets" ], "published": true, "lastmod": "2026-03-06" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://obg.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "opg", "type": "website", "title": "The Optimal Policy Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Policy", "description": "The Optimal Policy Generator (OPG) produces systematic public policy recommendations for jurisdictions at any level (country, state, city), generating prioritized enact/replace/repeal/maintain recommendations to maximize real after-tax median income growth and median healthy life years, based on quasi-experimental evidence from centuries of policy variation data.", "siteUrl": "https://opg.warondisease.org", "favicon": "https://opg.warondisease.org/assets/icons/dih-favicon.png", "ogImage": "https://opg.warondisease.org/assets/og/opg-og-1200x630.jpg", "pdfUrl": "https://opg.warondisease.org/opg-framework-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18603834", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Policy Evaluation, Causal Inference, Quasi-Experimental Methods, Evidence-Based Policy, Jurisdiction Analysis", "category": "Academic Paper, Public Policy, Political Science", "keywords": [ "policy-evaluation", "causal-inference", "quasi-experimental-methods", "synthetic-control", "difference-in-differences", "bradford-hill-criteria", "evidence-based-policy", "policy-recommendations", "jurisdiction-analysis", "policy-impact-score" ], "audience": "Researchers, Policy Makers, Political Scientists, Econometricians", "format": "Working Paper", "genre": "Political Science, Policy Analysis, Causal Inference", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "8b9558d9-6a2b-4581-bde7-11d79933d105", "cname": "opg-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/optimal-policy-generator-spec.qmd", "outputDir": "_site/opg", "publishing": { "ownSite": { "url": "https://opg.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18603834", "doi": "10.5281/zenodo.18603834" }, { "platform": "ssrn", "status": "pending", "url": "" } ], "journals": [ { "name": "Journal of Policy Analysis and Management", "tier": 2, "status": "target", "url": "" }, { "name": "American Political Science Review", "tier": 1, "status": "target", "url": "" }, { "name": "Journal of Politics", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/optimal-policy-generator-spec.qmd", "url": "https://opg.warondisease.org/appendix/optimal-policy-generator-spec.html", "title": "The Optimal Policy Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Policy", "description": "The Optimal Policy Generator (OPG) produces systematic public policy recommendations for jurisdictions at any level (country, state, city), generating prioritized enact/replace/repeal/maintain recommendations to maximize real after-tax median income growth and median healthy life years, based on quasi-experimental evidence from centuries of policy variation data.", "image": "https://opg.warondisease.org/assets/og-images/knowledge/appendix/optimal-policy-generator-spec-og-bw-academic.jpg", "sections": [ "Abstract", "The Two Welfare Metrics", "Why Only Two Metrics?", "Income Metric Definition", "Outcome Translation Methodology", "The Evidence Base: Centuries of Natural Policy Experiments", "Scale of Available Natural Experiments", "The OPG Pipeline", "Why This Hasn't Been Done Before", "System Overview", "What Policymakers See", "What Policy Analysts See", "Introduction", "Why Policy Ranking Fails Today", "Scale of Available Evidence", "Contributions", "Validation Status", "Related Work", "Existing Policy Evaluation Frameworks", "This Framework's Contribution", "Theoretical Framework", "The Policy Optimization Problem", "Evidence Aggregation Properties", "Information Value", "Core Methodology", "Policy-Outcome Data Structure", "Analysis Methods", "Bradford Hill Criteria Scoring Functions", "Causal Confidence Score (CCS) Calculation", "Jurisdiction Policy Inventory", "Tracking Current Policies by Jurisdiction", "Data Sources for Policy Status", "Handling Missing Data", "Policy Gap Analysis", "Comparing Current to Optimal", "Gap Types", "Priority Scoring", "Context Adjustment", "Recommendation Generation", "Recommendation Types", "Blocking Factors", "Similar Jurisdictions", "Recommended Tracking (for OPG Feedback)", "Optimal Jurisdictional Level for Policy Implementation", "The Subsidiarity Principle for Evidence Generation", "When Higher Levels Are Necessary", "Jurisdictional Level in Recommendations", "Policy Impact Score (Intermediate Metric)", "Overview", "Jurisdiction-Level PIS Calculation", "Always Report Both Metrics Separately", "Effect Estimate Standardization", "Quality Adjustment Factor", "Confounder Adjustment", "Global (Aggregate) PIS Calculation", "Pooled Effect Estimate", "Pooled PIS Across Jurisdictions", "Heterogeneity Statistics", "Evidence Grading", "Context-Specific Confidence", "Quality Requirements & Validation", "Minimum Thresholds for Inclusion", "Parallel Trends Testing (DiD)", "Pre-Treatment Fit (Synthetic Control)", "Placebo and Robustness Tests", "Interpreting Recommendations", "Priority Tiers", "Political Feasibility Notes", "Sequencing Guidance", "Effect Size Benchmarks", "Trial Prioritization", "Value of Information Calculation", "Natural Experiment Identification", "Recommended Pilot Jurisdictions", "Data Sources", "Primary Policy Databases", "Primary Outcome Databases", "Subnational Data", "Jurisdiction Policy Inventory Sources", "Limitations", "Oracle Capture Risk", "Confounding Severity", "Heterogeneous Effects", "Jurisdiction-Specific Caveats", "Time-Varying Effects", "Publication Bias", "Epistemic Limitations", "Validation Framework", "The Critical Question", "Addressing Adoption Bias", "Proposed Validation Study", "Prospective Pre-Registration", "Known Limitations Requiring Validation", "Continuous Improvement via Adoption Feedback", "Future Directions", "Validation Priorities", "Data Infrastructure", "Integration with Decision-Making", "Conclusion", "Acknowledgments", "References", "Appendix A: Worked Example - Texas Policy Recommendations", "Warning SYNTHETIC DATA - NOT EMPIRICAL FINDINGS", "Overview", "Texas Policy Inventory (Sample)", "Step 1: Calculate Policy Impact Scores", "Step 2: Apply Context Adjustment for Texas", "Step 3: Generate Recommendations", "ENACT (New Policies to Adopt)", "REPLACE (Policies to Modify)", "REPEAL (Policies to Remove)", "MAINTAIN (No Change Needed)", "Step 4: Summary Dashboard", "Interpretation", "Appendix B: OPG Analysis Workflow", "Complete OPG Pipeline", "Minimum Data Requirements Checklist", "Appendix C: Glossary" ], "published": true, "lastmod": "2026-03-05" } ], "pageCount": 1 }, { "id": "optimocracy", "type": "website", "title": "Optimocracy: Causal Inference on Cross-Jurisdictional Policy Data to Maximize Median Health and Wealth", "description": "Thousands of jurisdictions have made different policy and budget choices over decades, creating a natural experiment. Optimocracy applies causal inference to this cross-jurisdictional time-series data to identify which policies predict above-average median income and healthy life years. It then publishes evidence-based recommendations for every major vote, tracks politician alignment, and funds aligned candidates via SuperPAC, making suboptimal policy politically expensive while preserving democratic structures.", "siteUrl": "https://optimocracy.warondisease.org", "favicon": "https://optimocracy.warondisease.org/assets/icons/optimocracy-favicon.png", "ogImage": "https://optimocracy.warondisease.org/assets/og/optimocracy-og-1200x630.jpg", "pdfUrl": "https://optimocracy.warondisease.org/optimocracy-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18356213", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Mechanism Design, Algorithmic Governance, Public Policy, Political Economy", "category": "Academic Paper, Public Policy, Political Science, Economics", "keywords": [ "mechanism-design", "algorithmic-governance", "smart-contracts", "metric-optimization", "capture-resistance", "central-bank-independence", "goodharts-law", "decentralized-oracles", "political-dysfunction", "rent-seeking", "public-choice" ], "audience": "Researchers, Policy Makers, Economists, Political Scientists", "format": "Working Paper", "genre": "Political Science, Mechanism Design, Public Policy, Economics", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "c6e535bc-4503-4db8-833a-c1b93f5e0f10", "cname": "optimocracy-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/optimocracy-paper.qmd", "outputDir": "_site/optimocracy", "publishing": { "ownSite": { "url": "https://optimocracy.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18523075", "doi": "10.5281/zenodo.18356213" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Public Choice", "tier": 2, "status": "target", "url": "" }, { "name": "Games and Economic Behavior", "tier": 2, "status": "target", "url": "" }, { "name": "Journal of Political Economy", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/optimocracy-paper.qmd", "url": "https://optimocracy.warondisease.org/appendix/optimocracy-paper.html", "title": "Optimocracy: Causal Inference on Cross-Jurisdictional Policy Data to Maximize Median Health and Wealth", "description": "Thousands of jurisdictions have made different policy and budget choices over decades, creating a natural experiment. Optimocracy applies causal inference to this cross-jurisdictional time-series data to identify which policies predict above-average median income and healthy life years. It then publishes evidence-based recommendations for every major vote, tracks politician alignment, and funds aligned candidates via SuperPAC, making suboptimal policy politically expensive while preserving democratic structures.", "image": "https://optimocracy.warondisease.org/assets/og-images/knowledge/appendix/optimocracy-paper-og-retro-academic.jpg", "sections": [ "The Mechanism", "Why This Works", "The Problem: Political Dysfunction Tax", "Why Information Alone Fails", "The Scale of Welfare Loss: Empirical Foundations", "Quantifying the Political Dysfunction Tax", "Documented Welfare Losses by Policy Domain", "Bottom-Up Policy Cost Accounting", "Why Information Doesn't Solve the Problem", "Implications for Mechanism Design", "When Does Optimocracy Beat the Status Quo?", "Theoretical Foundations", "Precedents That Work", "Mechanism Design", "Architecture Overview", "The Verification Layer", "The Execution Layer", "Welfare Metrics", "Default Implementation: Two-Metric Welfare Function", "Advantages Over Political Governance", "Capture Resistance", "Time Consistency", "Transparency", "Depolarization", "Challenges and Failure Modes", "Why Goodhart's Law Doesn't Apply Here", "Oracle Capture (The Real Challenge)", "Democratic Legitimacy", "Testable Predictions", "Rejection Criteria", "The Wrapper Architecture: How Funding Works", "Campaign Funding Allocation Algorithm", "Political Economy: Making Reform Happen", "Why Buying Off the Opposition Works", "How the SuperPAC Makes This Concrete", "The Cost of Political Reform", "The Natural Reform Coalition", "Implementation Pathway", "Why Government Adoption Isn't Required", "Implementation Strategy", "Concrete First Deployment: The GiveWell Outcome Fund", "Conclusion", "What About AI?", "Appendix A: Technical Specification Sketch", "Budget and Policy Optimization: Two Complementary Frameworks", "Algorithmic Governance Threat Model", "Appendix B: Theoretical Background", "Historical Precedents: Technocratic Governance Failures", "Engaging with Impossibility Theorems", "Democratic Legitimacy: A Deeper Analysis", "Boundary Conditions for Algorithmic Governance", "Acknowledgments", "References" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://optimocracy.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "political-dysfunction-tax", "type": "website", "title": "The Political Dysfunction Tax", "description": "Quantifying the gap between current global governance and theoretical maximum welfare, estimating a 31-53% efficiency score and $97 trillion in annual opportunity costs.", "siteUrl": "https://political-dysfunction-tax.warondisease.org", "favicon": "https://political-dysfunction-tax.warondisease.org/assets/icons/political-dysfunction-tax-favicon.png", "ogImage": "https://political-dysfunction-tax.warondisease.org/assets/og/political-dysfunction-tax-og-1200x630.jpg", "pdfUrl": "https://political-dysfunction-tax.warondisease.org/political-dysfunction-tax.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18603840", "version": "1.0", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Governance Efficiency, Political Economy, Welfare Economics, Public Choice", "category": "Academic Paper, Public Policy, Political Science, Economics", "keywords": [ "governance-efficiency", "political-dysfunction", "welfare-economics", "opportunity-cost", "public-choice", "rent-seeking", "clinical-trials", "migration-economics", "regulatory-burden" ], "audience": "Researchers, Policy Makers, Economists, Political Scientists", "format": "Working Paper", "genre": "Political Science, Welfare Economics, Public Policy", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "1c74b376-7837-436e-b57b-8579b7a1939e", "cname": "political-dysfunction-tax-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/political-dysfunction-tax.qmd", "outputDir": "_site/political-dysfunction-tax", "publishing": { "ownSite": { "url": "https://political-dysfunction-tax.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18603840", "doi": "10.5281/zenodo.18603840" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Public Choice", "tier": 2, "status": "target", "url": "" }, { "name": "Journal of Political Economy", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/political-dysfunction-tax.qmd", "url": "https://political-dysfunction-tax.warondisease.org/appendix/political-dysfunction-tax.html", "title": "The Political Dysfunction Tax", "description": "Governance dysfunction imposes large per-person annual costs and suppresses long-run compounding. This paper quantifies the opportunity ledger and efficiency gap with model-linked parameters.", "image": "https://political-dysfunction-tax.warondisease.org/assets/og-images/knowledge/appendix/political-dysfunction-tax-og-retro-academic.jpg", "sections": [ "What This Costs You", "Introduction: The Mechanism Design of Civilizational Stagnation", "Part 1: The Waste Ledger (The \"Burned Capital\")", "Military Overspend: The Cost of Hegemony vs. Security", "Administrative Bloat and the Friction Economy", "Incarceration & Prohibition: The Economics of Human Caging", "Part 2: The Opportunity Ledger (The \"Buried Multipliers\")", "The Health Multiplier: The Trillion-Dollar Graveyard", "The Human Capital Multiplier: Unleashing Cognitive Stock", "Part 3: The Calculation ($E$)", "The Variables", "The Efficiency Score", "Comparative Balance Sheet: Status Quo vs. Optimocracy", "Analysis and Second-Order Insights", "The \"Parable of the Broken Window\" on Steroids", "The \"Buried\" Health Multiplier is the Critical Failure", "Security Theater vs. Solvency", "Conclusion", "See Also" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://political-dysfunction-tax.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "right-to-trial", "type": "website", "title": "Right to Trial & FDA Upgrade Act", "description": "Act to modernize medical research and treatment access through an open-source FDA.gov v2, giving patients the right to participate in trials.", "siteUrl": "https://right-to-trial.warondisease.org", "favicon": "https://right-to-trial.warondisease.org/assets/icons/dih-favicon.png", "ogImage": "https://right-to-trial.warondisease.org/assets/og-images/knowledge/appendix/right-to-trial-fda-upgrade-act-og-retro-academic.jpg", "pdfUrl": "https://right-to-trial.warondisease.org/right-to-trial-fda-upgrade-act.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "version": "1.0", "edition": "First Edition", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Clinical Trials, Drug Development, Healthcare Reform, Regulatory Policy, Patient Rights", "category": "Legislative Text, Public Policy, Healthcare Reform", "keywords": [ "right-to-trial", "fda-upgrade", "clinical-trials", "drug-development", "healthcare-reform", "regulatory", "patient-rights", "open-data", "decentralized-trials", "fda-v2" ], "audience": "Policy Makers, Healthcare Professionals, Patient Advocates, Researchers, General Public", "format": "Legislative Text", "genre": "Healthcare Policy, Regulatory Reform", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "f0cfd162-dc07-474f-9b19-367ce1c1616f", "cname": "right-to-trial-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/right-to-trial-fda-upgrade-act.qmd", "outputDir": "_site/right-to-trial", "publishing": { "ownSite": { "url": "https://right-to-trial.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "pending", "url": "", "doi": "" } ], "journals": [] }, "pages": [ { "path": "knowledge/appendix/right-to-trial-fda-upgrade-act.qmd", "url": "https://right-to-trial.warondisease.org/appendix/right-to-trial-fda-upgrade-act.html", "title": "Right to Trial & FDA Upgrade Act", "description": "Act to modernize medical research and treatment access through an open-source FDA.gov v2, giving patients the right to participate in trials.", "image": "https://right-to-trial.warondisease.org/assets/og-images/knowledge/appendix/right-to-trial-fda-upgrade-act-og-retro-academic.jpg", "tags": [ "clinical-trials", "drug-development", "policy", "healthcare-reform", "regulatory", "patient-rights", "fda-upgrade", "right-to-trial", "open-data" ], "sections": [ "TITLE I: SHORT TITLE; PURPOSE; FINDINGS; DEFINITIONS", "SEC. 101. SHORT TITLE", "SEC. 102. PURPOSE", "SEC. 103. FINDINGS", "SEC. 104. DEFINITIONS", "TITLE II: FDA Upgrade AND CLINICAL‑TRIAL INNOVATION", "SEC. 201. ACCELERATED ADOPTION OF ALTERNATIVE PRECLINICAL TEST METHODS", "SEC. 202. GUIDANCE ON DECENTRALISED, ADAPTIVE, AND REAL‑WORLD‑EVIDENCE TRIALS", "SEC. 203. PATIENT‑FOCUSED DRUG DEVELOPMENT AND GLOBAL COLLABORATION", "SEC. 204. FDA.gov v2 DECENTRALIZED HEALTH PROTOCOL AND REFERENCE IMPLEMENTATION", "SEC. 205. FDA-X PRIZE", "TITLE III: UNIVERSAL TRIAL ACCESS (RIGHT‑TO‑TRIAL PROGRAM)", "SEC. 301. UNIVERSAL ELIGIBILITY FOR INVESTIGATIONAL INTERVENTIONS", "SEC. 302. PATIENT PROTECTIONS, CONSENT, AND LIABILITY", "SEC. 303. FAIR ACCESS AND DISCOUNT ALGORITHMS", "SEC. 304. PATIENT COST CONTRIBUTION FOR TRIAL PARTICIPATION", "TITLE IV: GENERAL PROVISIONS", "SEC. 401. COORDINATION WITH EXISTING LAW", "SEC. 402. AUTHORIZATION OF APPROPRIATIONS AND STAGE‑GATED FUNDING", "SEC. 403. IMPLEMENTATION TIMELINE", "SEC. 404. STRATEGY FOR GLOBAL GOVERNANCE AND DECENTRALIZATION", "SEC. 405. SEVERABILITY", "SEC. 406. TRANSPARENCY IN REGULATORY ACTIONS LIMITING TREATMENT ACCESS", "REFERENCES" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://right-to-trial.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "us-efficiency-audit", "type": "website", "title": "United States Efficiency Audit", "description": "Systems audit estimating an annual U.S. efficiency gap of $4.9T, with $2.45T recoverable at OECD-median performance across direct spending waste, compliance burden, policy-induced GDP loss, and system inefficiency.", "siteUrl": "https://us-efficiency-audit.warondisease.org", "favicon": "https://us-efficiency-audit.warondisease.org/assets/icons/us-efficiency-audit-favicon.png", "ogImage": "https://us-efficiency-audit.warondisease.org/assets/og/us-efficiency-audit-og-1200x630.jpg", "pdfUrl": "https://us-efficiency-audit.warondisease.org/us-efficiency-audit.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18447476", "version": "1.0", "edition": "Working Draft", "copyright": "© 2025 The Institute for Accelerated Medicine", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Public Finance, Government Efficiency, Systems Analysis, Resource Allocation, Policy Analysis", "category": "Academic Paper, Public Policy, Economics, Systems Engineering", "keywords": [ "government-efficiency", "public-finance", "resource-allocation", "systems-analysis", "federal-spending", "policy-analysis", "monte-carlo-simulation", "efficiency-metrics", "OECD-benchmarks", "allocation-inefficiency" ], "audience": "Researchers, Policy Makers, Economists, Public Finance Analysts", "format": "Working Paper", "genre": "Public Finance, Systems Analysis, Policy Analysis, Economics", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "9a8ec013-54cd-4b7a-9364-fa13dc46bd92", "cname": "us-efficiency-audit-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/us-efficiency-audit.qmd", "outputDir": "_site/us-efficiency-audit", "publishing": { "ownSite": { "url": "https://us-efficiency-audit.warondisease.org", "status": "pending" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18522036", "doi": "10.5281/zenodo.18447476" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "econ.GN" } ], "journals": [ { "name": "Journal of Public Economics", "tier": 1, "status": "target", "url": "" }, { "name": "Public Choice", "tier": 2, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/us-efficiency-audit.qmd", "url": "https://us-efficiency-audit.warondisease.org/appendix/us-efficiency-audit.html", "title": "United States Efficiency Audit", "description": "Systems audit estimating an annual U.S. efficiency gap of $4.9T, with $2.45T recoverable at OECD-median performance across direct spending waste, compliance burden, policy-induced GDP loss, and system inefficiency.", "image": "https://us-efficiency-audit.warondisease.org/assets/og-images/knowledge/appendix/us-efficiency-audit-og.jpg", "sections": [ "Executive Summary", "Dysfunction Category Breakdown", "Aggregate Metrics", "Interpretation Note", "System Specifications", "Designed Function", "Why Two Metrics Are Sufficient", "Input-Output Measurement", "Methodology", "Category Framework: Why Distinctions Matter", "Engineering Loss Categories", "Aggregate Efficiency Gap Calculation", "Methodological Note: Additive Categories", "Valuation Standards", "Direct Federal Spending Waste", "Components", "Compliance Burden on Private Sector", "Components", "Policy-Induced GDP Loss", "Components", "System Inefficiency", "Components", "Subsystem Cross-Reference", "Subsystem Audit: Defense", "Loss Category: Leakage (Audit Failure)", "Loss Category: Conversion Inefficiency (F-35 Program)", "Loss Category: Idle/Standby (Overseas Basing)", "Loss Category: Parasitic (Strategic Misalignment)", "Defense Subsystem Summary", "Subsystem Audit: Healthcare Administration", "Loss Category: Friction (Administrative Overhead)", "Loss Category: Leakage (Medicare Advantage Upcoding)", "Loss Category: Leakage (Improper Payments)", "Healthcare Subsystem Summary", "Subsystem Audit: Justice and Prohibition", "Loss Category: Conversion Inefficiency (Drug Prohibition)", "Loss Category: Negative Work (Mass Incarceration)", "Loss Category: Leakage (Civil Asset Forfeiture)", "Justice Subsystem Summary", "Subsystem Audit: Regulatory and Tax Compliance", "Loss Category: Friction (Tax Compliance)", "Loss Category: Friction (Housing/Zoning Misallocation)", "Loss Category: Idle (NEPA Permitting Delays)", "Loss Category: Parasitic (Jones Act)", "Regulatory Subsystem Summary", "Subsystem Audit: Subsidies and Transfers", "Loss Category: Parasitic (Fossil Fuel Subsidies)", "Loss Category: Parasitic (Agricultural Subsidies)", "Loss Category: Negative Work (Tariffs and Corporate Welfare)", "Subsidies Subsystem Summary", "Aggregate Efficiency Calculation", "Monte Carlo Simulation Parameters", "Simulation Results", "Tax Compliance", "Housing/Zoning", "Healthcare", "Drug War", "Efficiency Rating Calculation", "Human Cost Quantification (Economic Equivalents)", "Reallocation Potential", "Context Comparisons", "Opportunity Cost in Healthy Life Years", "Structural Factors", "Severed Feedback Loops", "Principal-Agent Misalignment", "Measurement Failure", "Monopoly Dynamics", "Time Horizon Mismatch", "Confidence Intervals and Limitations", "Estimate Confidence by Subsystem", "What This Analysis Excludes", "Methodological Limitations", "See Also" ], "published": true, "lastmod": "2026-03-05" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://us-efficiency-audit.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 }, { "id": "wishocracy", "type": "website", "title": "Wishocracy: Solving the Democratic Principal-Agent Problem Through Pairwise Preference Aggregation", "description": "Representative democracy suffers from an inescapable principal-agent problem where elected officials' incentives diverge from citizen welfare. Wishocracy introduces RAPPA (Randomized Aggregated Pairwise Preference Allocation), which aggregates citizen preferences through cognitively tractable pairwise comparisons and creates accountability via Citizen Alignment Scores that channel electoral resources toward politicians who actually represent what citizens want.", "siteUrl": "https://wishocracy.warondisease.org", "favicon": "https://wishocracy.warondisease.org/assets/icons/wishocracy-favicon.png", "ogImage": "https://wishocracy.warondisease.org/assets/og/wishocracy-og-1200x630.jpg", "pdfUrl": "https://wishocracy.warondisease.org/wishocracy-rappa-paper.pdf", "author": "Mike P. Sinn", "authorEmail": "mike@warondisease.org", "authorUrl": "https://mikesinn.com", "orcid": "0009-0006-0212-1094", "doi": "10.5281/zenodo.18205881", "version": "0.9", "edition": "Working Draft", "copyright": "© 2025 Mike P. Sinn", "copyrightYear": "2025", "license": "CC BY-NC 4.0", "licenseUrl": "https://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Institute for Accelerated Medicine", "publisherUrl": "https://acceleratedmedicine.org", "subject": "Mechanism Design, Collective Intelligence, Direct Democracy, Principal-Agent Problem, Public Resource Allocation", "category": "Academic Paper, Public Policy, Political Science", "keywords": [ "mechanism-design", "collective-intelligence", "direct-democracy", "principal-agent-problem", "preference-aggregation", "participatory-budgeting", "analytic-hierarchy-process", "democratic-resource-allocation", "wishocracy", "RAPPA", "democratic-innovation" ], "audience": "Researchers, Policy Makers, Democracy Innovators, Political Scientists", "format": "Working Paper", "genre": "Political Science, Mechanism Design, Public Policy", "language": "en-US", "twitterSite": "https://x.com/warondisease", "twitterCreator": "https://x.com/warondisease", "netlify": { "siteId": "6d3175fc-5866-4d09-985d-aebe008a4966", "cname": "wishocracy-warondisease-org.netlify.app" }, "indexSource": "knowledge/appendix/wishocracy-paper.qmd", "outputDir": "_site/wishocracy", "publishing": { "ownSite": { "url": "https://wishocracy.warondisease.org", "status": "deployed" }, "preprints": [ { "platform": "zenodo", "status": "auto-uploaded", "url": "https://zenodo.org/record/18523095", "doi": "10.5281/zenodo.18205881" }, { "platform": "ssrn", "status": "pending", "url": "" }, { "platform": "arxiv", "status": "pending", "category": "cs.GT" } ], "journals": [ { "name": "Social Choice and Welfare", "tier": 2, "status": "target", "url": "" }, { "name": "Public Choice", "tier": 2, "status": "target", "url": "" }, { "name": "American Political Science Review", "tier": 1, "status": "target", "url": "" } ] }, "pages": [ { "path": "knowledge/appendix/wishocracy-paper.qmd", "url": "https://wishocracy.warondisease.org/appendix/wishocracy-paper.html", "title": "Wishocracy: Solving the Democratic Principal-Agent Problem Through Pairwise Preference Aggregation", "description": "Representative democracy suffers from an inescapable principal-agent problem where elected officials' incentives diverge from citizen welfare. Wishocracy introduces RAPPA (Randomized Aggregated Pairwise Preference Allocation), which aggregates citizen preferences through cognitively tractable pairwise comparisons and creates accountability via Citizen Alignment Scores that channel electoral resources toward politicians who actually represent what citizens want.", "image": "https://wishocracy.warondisease.org/assets/og-images/knowledge/appendix/wishocracy-paper-og-retro-academic.jpg", "sections": [ "The Analytic Hierarchy Process", "The Preference Intensity Problem", "Collective Intelligence and the Wisdom of Crowds", "Related Work and Positioning in the Literature", "Core Mechanism", "Scenario: Federal Budget Preferences", "Formal Properties", "Formal Model", "Computational Complexity and Scalability", "Comparative Information & Welfare Analysis", "Information-Theoretic Superiority", "Welfare Maximization: The \"Median vs. Mean\" Proof", "Principal-Agent Cost Elimination", "Porto Alegre Participatory Budgeting", "Taiwan's Digital Democracy Experiments", "Stanford Participatory Budgeting Platform Research", "Reference Implementation: Wishocracy.org", "Category Selection and Validation Methodology", "Zero-Funding Filter Optimization", "Hierarchical Category Structure", "Framing Bias and Mitigation", "Participation and Digital Divide", "Manipulation and Sybil Attacks", "Preference Laundering and Manufactured Consent", "Complexity of Real Policy Trade-offs", "Legitimacy and Accountability", "Failure Modes and Robustness", "Historical Direct Democracy Failures and RAPPA's Structural Responses", "Why Information Alone Fails: Politicians Respond to Incentives", "Three-Phase Implementation", "Phase 1: Informational (Preference Gap Documentation)", "Phase 2: Accountability Scoring (Politician Alignment Ratings)", "Phase 3: Incentive Alignment (Integration with Incentive Alignment Bonds)", "Why Federal-Scale Priorities", "Evaluation Framework", "Preference Aggregation Quality", "Accountability System Effectiveness", "Incentive Alignment Impact", "Connection to Incentive Alignment Bonds", "Connection to Optimocracy", "References" ], "published": true, "lastmod": "2026-03-08" }, { "path": "knowledge/appendix/parameters-and-calculations.qmd", "url": "https://wishocracy.warondisease.org/appendix/parameters-and-calculations.html", "title": "Methodology, Parameters, and Calculations", "description": "Parameter definitions, formulas, uncertainty ranges, and data sources.", "sections": [ "Overview", "Quick Navigation", "Calculated Values", "Additional Drug Approvals from Cost Elimination: 20 drugs/year", "Cell Therapy Combinations: 500 thousand combinations", "Engagement Rate: 10%", "Expected Engaged Implementers: 14.5 people", "Potential Implementers: 2.98 thousand people", "P(At Least One Engages): 100%", "10-Year Direct Encounter Probability: 4.89%", "P(No Implementer Engages): 4.63e-05%", "Annual Chronic Disease Patients Treated: 982 million people", "Clinical Trial Cost Per Approved Drug: $1.2B", "Annual Cost Per Clinical Trial Participant: $31.6K", "Combination Therapy Space: 45.1 billion combinations", "Pairwise Drug Combinations: 45.1 million combinations", "Combination Therapy Exploration Time (Current): 13.7 million years", "Known Safe Exploration Time (Current): 2.88 thousand years", "Current Patient Participation Rate in Clinical Trials: 0.0792%", "Total Exploration Time (Current): 15.6 thousand years", "Years Until Destructive Economy Reaches 25% of GDP: 8 years", "Years Until Destructive Economy Reaches 50% of GDP: 15 years", "Total Annual Decentralized Framework for Drug Assessment Operational Costs: $40M", "Decentralized Framework for Drug Assessment Annual Benefit: R&D Savings: $58.6B", "dFDA Combined Treatment Discovery Speedup Multiplier: 17.3x", "dFDA Direct Funding Cost per DALY: $0.842", "dFDA Direct Funding NPV (Exploration Period): $476B", "Direct Funding ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 178k:1", "Direct Funding Cost-Effectiveness vs Bed Nets: 106x", "Total DALYs Lost from Disease Eradication Delay: 7.94 billion DALYs", "Total Deaths from Disease Eradication Delay: 416 million deaths", "Total Economic Loss from Disease Eradication Delay: $1.19 quadrillion", "Years Lived with Disability During Disease Eradication Delay: 873 million years", "Years of Life Lost from Disease Eradication Delay: 7.07 billion years", "dFDA New Treatments Per Year: 185 diseases/year", "Known Safe Exploration Time (dFDA): 234 years", "Maximum Trial Capacity Multiplier (Physical Limit): 566x", "Decentralized Framework for Drug Assessment Annual Net Savings (R&D Only): $58.6B", "Decentralized Framework for Drug Assessment Total NPV Annual OPEX: $40M", "NPV of Decentralized Framework for Drug Assessment Benefits (R&D Only, 10-Year Discounted): $389B", "NPV Net Benefit (R&D Only): $389B", "Decentralized Framework for Drug Assessment Present Value of Annual OPEX Over 10 Years: $342M", "Decentralized Framework for Drug Assessment Total NPV Cost: $611M", "Decentralized Framework for Drug Assessment Total NPV Upfront Costs: $270M", "Decentralized Framework for Drug Assessment Overhead Percentage of Treaty Funding: 0.147%", "dFDA Patients Fundable Annually: 23.4 million patients/year", "dFDA Therapeutic Space Exploration Time: 36 years", "Daily R&D Savings from Trial Cost Reduction: $161M", "ROI from Decentralized Framework for Drug Assessment R&D Savings Only: 637:1", "Total Infrastructure Cost per Patient (Annual): $8.64", "Total Infrastructure Cost per Patient (Monthly): $0.72", "Total Exploration Time (dFDA): 1.27 thousand years", "Decentralized Framework for Drug Assessment Maximum Trials per Year: 40.7 thousand trials/year", "DALYs Averted from Trial Capacity Increase: 543 billion DALYs", "Economic Value from Trial Capacity Increase: $81.5 quadrillion", "Lives Saved from Trial Capacity Increase: 10.3 billion deaths", "Trial Capacity Multiplier: 12.3x", "Total DALYs from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 565 billion DALYs", "Total Economic Benefit from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: $84.8 quadrillion", "Total Lives Saved from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 10.7 billion deaths", "Suffering Hours Eliminated from Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Higher Trial Throughput: 1.93 quadrillion hours", "dFDA Average Total Timeline Shift: 212 years", "dFDA Treatment Timeline Acceleration: 204 years", "dFDA Trial Cost Reduction Factor: 44.1x", "dFDA Trial Cost Reduction Percentage: 97.7%", "dFDA Annual Trial Subsidies: $21.8B", "dFDA Valley of Death Rescue Multiplier: 1.4x", "Patients Fundable Annually: 23.4 million patients/year", "Medical Research Percentage of Treaty Funding: 80%", "Annual Funding for Pragmatic Clinical Trials: $21.8B", "Annual Clinical Trial Patient Subsidies: $21.7B", "Patient Trial Subsidies Percentage of Treaty Funding: 79.9%", "Diseases Without Effective Treatment: 6.65 thousand diseases", "Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths: 18.4k:1", "Ratio of Annual Disease Deaths to War Deaths: 225:1", "Coverage Factor of Treaty Funding vs Decentralized Framework for Drug Assessment OPEX: 680:1", "Total Drugs Approved Since 1962: 3.1 thousand drugs", "Drug Cost Increase: 1980s to Current: 13.4x", "Drug Cost Increase: Pre-1962 to Current: 105x", "Possible Drug-Disease Combinations: 9.5 million combinations", "Earth Average Income at Year 20: $20.5K", "Earth Cumulative Lifetime Income (Per Capita): $1.18M", "Earth GDP at Year 20: $188T", "Cumulative Efficacy Testing Cost (1962-2024): $4.84T", "Efficacy Lag Deaths (9/11 Equivalents): 34.1 thousand 9/11s", "Treatment Delay YLD - Annual: 2.01 billion DALYs", "Emerging Modality Combinations: 42 million combinations", "Epigenetic Therapy Combinations: 1.5 million combinations", "Total Deaths from Historical Progress Delays: 102 million deaths", "Total Economic Loss from Historical Progress Delays: $259T", "Therapeutic Frontier Exploration Ratio: 0.342%", "FDA Efficacy Testing to Oxford RECOVERY Trial Time Multiplier: 32.8x", "Expected GDP vs Earth Multiplier (Year 20): 51x", "Expected GDP at Year 20 (Probability-Weighted): $9.62 quadrillion", "Gene Therapy Combinations: 20 million combinations", "Total Annual Conflict Deaths Globally: 245 thousand deaths/year", "Total Annual Cost of War Worldwide: $11.4T", "Annual Cost of Combat Deaths: $2.34T", "Annual Cost of State Violence Deaths: $27B", "Annual Cost of Terror Deaths: $83B", "Total Annual Human Life Losses from Conflict: $2.45T", "Total Annual Infrastructure Destruction: $1.88T", "Total Annual Trade Disruption: $616B", "Total Annual Direct War Costs: $7.66T", "Total Annual Indirect War Costs: $3.7T", "Global Average Hourly Income: $7.19", "Global Average Income (2025 Baseline): $14.4K", "Average Remaining Years (Median Person): 48.5 years", "Cost per Life Saved by Medical Research: $16.1K", "Global Destructive Economy (2025): $13.2T", "Destructive Economy as % of GDP: 11.5%", "Global Deaths per Minute from Disease: 104 deaths/minute", "Annual Welfare Cost of Avoidable Disease: $400T", "Annual Global Industry Spending on Clinical Trials: $55.5B", "Per Capita Military Spending Globally: $340", "Global Military Spending After 1% Treaty Reduction: $2.69T", "Global Political Reform Investment: $128B", "Total Annual Cost of War and Disease: $412T", "Healthcare vs Military Multiplier Ratio: 7.17x", "IAB Mechanism Benefit-Cost Ratio: 230:1", "Annual IAB Political Incentive Funding: $2.72B", "IAB vs Defense Lobbying Ratio at 1% Treaty: 21.4x", "Ratio of Industry to Government Clinical Trials Spending: 12.3:1", "Expected Ready Launch Principals: 5.85 people", "Required Lead Principals for Launch: 4 people", "P(Launch Coalition Forms): 86.3%", "Ready Probability per High-Alignment Principal: 19.5%", "Life Expectancy Gain Rate (1883-1962): 0 years/decade", "Life Expectancy Gain Rate (1962-2019): 0 years/decade", "Medical Research Spending as Percentage of Total Disease Burden: 0.0164%", "Ratio of Military to Clinical Trials Spending: 45.3:1", "Ratio of Military to Government Clinical Trials Spending: 604:1", "Ratio of Military Spending to Medical Research Spending: 40.3:1", "Misallocation Factor: Cost to Kill vs Cost to Save: 2.9kx", "Moronia Path Probability (Year 20 EV Model): 10%", "mRNA Therapeutic Combinations: 20 million combinations", "NIH Traditional Trial Maximum Efficiency vs Pragmatic (%): 2.27%", "Annual Peace Dividend from 1% Reduction in Total War Costs: $114B", "Conflict Reduction Benefits from 1% Less Military Spending: $86.4B", "Annual Savings from 1% Reduction in Direct War Costs: $76.6B", "Annual Savings from 1% Reduction in Environmental Damage: $1B", "Annual Savings from 1% Reduction in Human Casualties: $24.5B", "Annual Savings from 1% Reduction in Indirect War Costs: $37B", "Annual Savings from 1% Reduction in Infrastructure Destruction: $18.8B", "Annual Savings from 1% Reduction in Lost Economic Growth: $27.2B", "Annual Savings from 1% Reduction in Lost Human Capital: $3B", "Annual Savings from 1% Reduction in PTSD and Mental Health Costs: $2.32B", "Annual Savings from 1% Reduction in Refugee Support Costs: $1.5B", "Annual Savings from 1% Reduction in Trade Disruption: $6.16B", "Annual Savings from 1% Reduction in Veteran Healthcare Costs: $2B", "Peace Trajectory Total Differential (20yr): $16.3T", "Personal Lifetime Wealth (QALY-Based): $3M", "US Per Capita Chronic Disease Cost: $12.2K", "US Per Capita Mental Health Cost: $1.04K", "Annual Lives Saved by Pharmaceuticals: 12.4 million deaths", "Global Governance Efficiency Score: 51.9%", "Global Opportunity Cost as % of GDP: 87.8%", "Global Opportunity Cost Total: $101T", "Adjusted Realized Welfare: $109T", "Theoretical Maximum Welfare (Conservative): $210T", "Global Waste Total (Efficiency Accounting): $6.2T", "Political Dysfunction Tax per Household of Four (Annual): $50.5K", "Political Dysfunction Tax per Person (Annual): $12.6K", "Percentage Military Spending Cut After WW2: 87.6%", "Pragmatic Trial Cost per QALY (RECOVERY): $4", "RECOVERY Trial Cost Reduction Factor: 82x", "RECOVERY Trial Total QALYs Generated: 5 million QALYs", "Sharing Breakeven (1 in N): 248M:1", "Sharing Breakeven Probability: 4.03e-09 probability", "Sharing Opportunity Cost: $0.06", "Sharing Upside/Downside Ratio: 248.2Mx", "Status Quo Average Years to First Treatment: 222 years", "Status Quo Therapeutic Space Exploration Time: 443 years", "Thalidomide DALYs Per Event: 41.8 thousand DALYs", "Thalidomide Deaths Per Event: 360 deaths", "Thalidomide Survivors Per Event: 540 cases", "Thalidomide US Cases Prevented: 900 cases", "Thalidomide YLD Per Event: 13 thousand years", "Thalidomide YLL Per Event: 28.8 thousand years", "Total Global Research Funding (Baseline + 1% treaty Funding): $94.7B", "Total Testable Therapeutic Space: 51.5 million combinations", "Annual Funding from 1% of Global Military Spending Redirected to DIH: $27.2B", "Treaty System Benefit Multiplier vs Childhood Vaccination Programs: 11.5x", "Amortized Annual Treaty Campaign Cost: $250M", "Total 1% Treaty Campaign Cost: $1B", "Target Voting Bloc Size for Campaign: 280 million of people", "Cost per DALY Averted (Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput): $0.00177", "Cumulative Treaty Funding over 20 Years with IAB Ratchet Expansion: $3.16T", "Expected Cost per DALY (Risk-Adjusted): $0.177", "Expected Treaty ROI (Risk-Adjusted): 848k:1", "Expected Cost-Effectiveness vs Bed Nets Multiplier: 503x", "Annual Lives Saved from 1% Reduction in Conflict Deaths: 2.45 thousand lives/year", "Treaty Path Average Income at Year 20: $339K", "Treaty Path CAGR (20 Years): 17.9%", "Treaty Path Cumulative Lifetime Income (Per Capita): $16.1M", "Treaty Path vs Earth GDP Multiplier (Year 20): 16.5x", "Treaty Path GDP at Year 20: $3.11 quadrillion", "Treaty Path Lifetime Income Gain (Per Capita): $14.9M", "Treaty Path Lifetime Income Multiplier: 13.5x", "1% treaty Basic Annual Benefits (Peace + R&D Savings): $172B", "Annual QALYs Gained from Peace Dividend: 85.6 thousand QALYs/year", "Treaty Ratchet Funding Multiplier (20yr): 5.8x", "Treaty Ratchet Premium over 20 Years: $2.61T", "Treaty ROI - Historical Rate (Existing Drugs): 259k:1", "Treaty ROI - Elimination of Efficacy Lag Plus Earlier Treatment Discovery from Increased Trial Throughput: 84.8M:1", "Total Annual Treaty System Costs: $290M", "Cost-Effectiveness vs Bed Nets Multiplier: 50.3kx", "Treaty Campaign Leverage vs Direct Funding: 476x", "Cumulative Trial Capacity Years Over 20 Years: 247 years", "Ratio of Type II Error Cost to Type I Error Benefit: 3.07k:1", "Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024): 2.59 million DALYs", "Unexplored Therapeutic Frontier: 99.7%", "US Congress Full Advocacy Cost: $5.35B", "US Federal Spending per Capita: $20.3K", "US Discretionary Efficiency: 40.5%", "Discretionary Waste (%): 59.5%", "US Governance Efficiency (GDP): 83%", "Category 1: Direct Spending Waste: $1.01T", "Category 2: Compliance Burden: $1.13T", "Category 3: GDP Loss: $1.56T", "Category 4: System Inefficiency: $1.2T", "US Waste (% GDP): 17%", "US Waste (QALY Equivalents): 49 million QALYs", "US Gov Waste (Raw Total): $4.9T", "Recoverable Capital: $2.45T", "US Government Waste (Total): $4.9T", "US Waste (VSL Equivalents): 357 thousand people", "Efficiency Gap / Treaty Funding: 180:1", "US Major Diseases Total Annual Cost: $1.25T", "Current US Military Spending vs Pre-WW2 Baseline (Multiplier): 30.6x", "US Political Reform Investment (Total): $25.5B", "US Senate Treaty Advocacy Cost: $670M", "Expected Value of a Vote (US): $0.000338", "Annual VICTORY Incentive Alignment Bond Payout: $2.72B", "Annual Return Percentage for VICTORY Incentive Alignment Bondholders: 272%", "Lives Saved per Voter: 38.4 lives", "Suffering Hours Prevented per Voter: 6.9 million hours", "Cumulative War Costs over 20 Years (Current Trajectory): $227T", "War Costs Saved via Peace Trajectory (20yr): $13.2T", "Global Patients Willing to Participate in Clinical Trials: 1.08 billion people", "Wishonia Disease Cure Fraction (20yr, Full Implementation): 100%", "Wishonia Military Reallocation Physical Max Share: 87.6%", "Wishonia Path Average Income at Year 20: $1.16M", "Wishonia Path CAGR (20 Years): 25.4%", "Wishonia Path Cumulative Lifetime Income (Per Capita): $53.3M", "Wishonia Path vs Earth GDP Multiplier (Year 20): 56.7x", "Wishonia Path GDP at Year 20: $10.7 quadrillion", "Wishonia Path Lifetime Income Gain (Per Capita): $52.1M", "Wishonia Path Lifetime Income Multiplier: 45x", "Wishonia Path vs Treaty Path GDP Multiplier (Year 20): 3.43x", "External Data Sources", "ADAPTABLE Trial Cost per Patient: $929", "ADAPTABLE Trial Total Cost: $14M", "Antidepressant Trial Exclusion Rate: 86.1%", "Average Annual Stock Market Return: 10%", "Baseline Annual Lives Saved by Pharmaceuticals: 12 deaths/year", "Bed Nets Cost per DALY: $89", "Total Annual Value of Unpaid Caregiving in US: $600B", "Number of Unpaid Caregivers in US: 38 million people", "Average Monthly Hours of Unpaid Family Caregiving in US: 20 hours/month", "Estimated Replacement Cost per Hour of Caregiving: $25", "Global Billionaire Count: 2.78 thousand people", "Estimated Annual Global Economic Benefit from Childhood Vaccination Programs: $15B", "Return on Investment from Childhood Vaccination Programs: 13:1", "Disability Weight for Untreated Chronic Conditions: 0.35 weight", "CPI Multiplier: 1980 to 2024: 3.8:1", "Current Active Trials at Any Given Time: 10 thousand trials", "Current Clinical Trial Participation Rate: 0.06%", "Global Population with Chronic Diseases: 2.4 billion people", "Average Annual New Drug Approvals Globally: 50 drugs/year", "Current Global Clinical Trials per Year: 3.3 thousand trials/year", "Current Trial Abandonment Rate: 40%", "Annual Global Clinical Trial Participants: 1.9 million patients/year", "Annual Defense Industry Lobbying Spending: $127M", "Deworming Cost per DALY: $55", "dFDA Pragmatic Trial Cost per Patient: $929", "Disease Burden as % of GDP: 13%", "DOT VSL: $13.7M", "Drug Development Cost (1980s): $194M", "Drug Discovery to Approval Timeline: 14 years", "Drug Repurposing Success Rate: 30%", "Economic Multiplier for Education Investment: 2.1x", "Economic Multiplier for Healthcare Investment: 4.3x", "Economic Multiplier for Infrastructure Investment: 1.6x", "Economic Multiplier for Military Spending: 0.6x", "Regulatory Delay for Efficacy Testing Post-Safety Verification: 8.2 years", "FDA-Approved Drug Products: 20 thousand products", "FDA-Approved Unique Active Ingredients: 1.65 thousand compounds", "FDA GRAS Substances: 635 substances", "FDA Phase 1 to Approval Timeline: 10.5 years", "Givewell Average Cost per Life Saved Across Top Charities: $4.5K", "Givewell Cost per Life Saved (Maximum): $5.5K", "Givewell Cost per Life Saved (Minimum): $3.5K", "Annual Deaths from Active Combat Worldwide: 234 thousand deaths/year", "Annual Deaths from State Violence: 2.7 thousand deaths/year", "Annual Deaths from Terror Attacks Globally: 8.3 thousand deaths/year", "Global Annual DALY Burden: 2.88 billion DALYs/year", "Annual Deaths from All Diseases and Aging Globally: 55 million deaths/year", "Annual Environmental Damage and Restoration Costs from Conflict: $100B", "Annual Infrastructure Damage to Communications from Conflict: $298B", "Annual Infrastructure Damage to Education Facilities from Conflict: $234B", "Annual Infrastructure Damage to Energy Systems from Conflict: $422B", "Annual Infrastructure Damage to Healthcare Facilities from Conflict: $166B", "Annual Infrastructure Damage to Transportation from Conflict: $487B", "Annual Infrastructure Damage to Water Systems from Conflict: $268B", "Annual Lives Saved by Medical Research Globally: 4.2 million lives/year", "Annual Lost Economic Growth from Military Spending Opportunity Cost: $2.72T", "Annual Lost Productivity from Conflict Casualties: $300B", "Annual PTSD and Mental Health Costs from Conflict: $232B", "Annual Refugee Support Costs: $150B", "Annual Trade Disruption Costs from Currency Instability: $57.4B", "Annual Trade Disruption Costs from Energy Price Volatility: $125B", "Annual Trade Disruption Costs from Shipping Disruptions: $247B", "Annual Trade Disruption Costs from Supply Chain Disruptions: $187B", "Annual Veteran Healthcare Costs: $200B", "Annual Days of Chronic Disease Therapy: 1.28 trillion days", "Annual Global Spending on Clinical Trials: $60B", "Cybercrime Cost CAGR: 15%", "Global Cybercrime Costs (2025): $10.5T", "Global Daily Deaths from Disease and Aging: 150 thousand deaths/day", "Global Annual Direct Medical Costs of Disease: $9.9T", "Global Annual Productivity Loss from Disease: $5T", "Global GDP (2025): $115T", "Annual Global Government Spending on Clinical Trials: $4.5B", "Global Household Wealth: $454T", "Global Life Expectancy (2024): 79 years", "Global Median Age (2024): 30.5 years", "Global Government Medical Research Spending: $67.5B", "Global Military Spending in 2024: $2.72T", "Military Spending Real CAGR (10-Year): 3.4%", "Annual Global Nonprofit Spending on Clinical Trials: $3.5B", "Annual Global Pharmaceutical R&D Spending: $300B", "Global Population in 2024: 8 billion of people", "Global Population 2045 (Projected): 9.2 billion of people", "Critical Mass Threshold for Social Change: 3.5%", "Annual Global Spending on Symptomatic Disease Treatment: $8.2T", "YLD Proportion of Total DALYs: 0.39 proportion", "Estimated Total Economic Impact of Human Genome Project: $1T", "Human Interactome Targeted by Drugs: 12%", "ICD-10 Total Codes: 14 thousand codes", "Life Extension from Treaty Research Acceleration: 20 years", "Maximum Annual Lobbyist Salary Range: $2M", "Minimum Annual Lobbyist Salary Range: $500K", "Return on Investment from Measles Vaccination Programs: 14:1", "Medical QALY Threshold: $100K", "Annual Productivity Loss per Capita from Mental Health Issues: $2K", "NATO Defense Spending (2024): $1.51T", "Diseases Getting First Treatment Per Year: 15 diseases/year", "NIH Annual Budget: $47B", "NIH Clinical Trials Spending Percentage: 3.3%", "NIH Standard Research Cost per QALY: $50K", "Oxford RECOVERY Trial Duration: 3 months", "Patient Willingness to Participate in Clinical Trials: 44.8%", "Pharma Drug Development Cost (Current System): $2.6B", "Pharma Average Drug Revenue (Current System): $6.7B", "Annual Life-Years Saved by Pharmaceuticals: 149 million life-years", "Pharma ROI (Current System): 1.2%", "Pharma Drug Success Rate (Current System): 10%", "Phase I-Passed Compounds Globally: 7.5 thousand compounds", "Phase I Safety Trial Duration: 2.3 years", "Phase 2/3 Share of Clinical Trial Costs: 69%", "Phase 3 Trial Total Cost (Minimum): $20M", "Pragmatic Trial Median Cost per Patient (PMC Review): $97", "Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs: 39:1", "Global Fossil Fuel Subsidies: $1.3T", "Global Health Opportunity Cost: $34T", "Global Lead Poisoning Cost: $6T", "Global Migration Opportunity Cost: $57T", "Global Science Opportunity Cost: $4T", "Political Success Probability: 1%", "Post-Office Career Value (per politician): $10M", "Post-1962 Drug Approval Reduction: 70%", "Pre-1962 Drug Development Cost (1980 Dollars): $6.5M", "Pre-1962 Drug Development Cost (2024 Dollars): $24.7M", "Pre-1962 Physician Count (Unverified): 144 thousand physicians", "Total Number of Rare Diseases Globally: 7 thousand diseases", "Recovery Trial Cost per Patient: $500", "RECOVERY Trial Global Lives Saved: 1 million lives", "RECOVERY Trial Total Cost: $20M", "Mean Age of Preventable Death from Post-Safety Efficacy Delay: 62 years", "Pre-Death Suffering Period During Post-Safety Efficacy Delay: 6 years", "September 11 Deaths: 2.98 thousand people", "Singapore GDP per Capita (PPP): $105K", "Singapore Govt Spending (% GDP): 1500%", "Singapore Life Expectancy: 84.1 years", "Return on Investment from Smallpox Eradication Campaign: 280:1", "Total Economic Benefit from Smallpox Eradication Campaign: $1.42B", "Estimated Annual Global Economic Benefit from Smoking Cessation Programs: $12B", "Standard Economic Value per QALY: $150K", "Standard QALYs per Life Saved: 35 QALYs/life", "Annual Cost of Sugar Subsidies per Person: $10", "Switzerland's Defense Spending as Percentage of GDP: 0.7%", "Switzerland GDP per Capita: $93K", "Switzerland Govt Spending (% GDP): 3500%", "Switzerland Life Expectancy: 84 years", "Switzerland Median Income (PPP): $65K", "Deaths from 9/11 Terrorist Attacks: 3 thousand deaths", "Thalidomide Cases Worldwide: 15 thousand cases", "Thalidomide Disability Weight: 0.4:1", "Thalidomide Mortality Rate: 40%", "Thalidomide Survivor Lifespan: 60 years", "US Population Share 1960: 6%", "Phase 3 Cost per Patient: $41K", "Treatment Disability Reduction: 0.25 weight", "US Alzheimer's Annual Cost: $355B", "US Cancer Annual Cost: $208B", "US Annual Chronic Disease Spending: $4.1T", "US Diabetes Annual Cost: $327B", "US Federal Spending (FY2024): $6.8T", "US Federal Discretionary Spending (FY2024): $1.7T", "US GDP (2024): $28.8T", "US Govt Spending (% GDP): 3800%", "Agricultural Subsidies Deadweight Loss: $75B", "Corporate Welfare Waste: $181B", "Drug War Cost: $90B", "Fossil Fuel Subsidies (Explicit): $50B", "Healthcare System Inefficiency: $1.2T", "Housing/Zoning Restrictions Cost: $1.4T", "Military Overspend: $615B", "Regulatory Red Tape Waste: $580B", "Tariff Cost (GDP Loss): $160B", "Tax Compliance Waste: $546B", "US Heart Disease Annual Cost: $363B", "US Life Expectancy (1880): 39.4 years", "US Life Expectancy (1962): 70.1 years", "US Life Expectancy (2019): 78.9 years", "US Life Expectancy: 77.5 years", "US Median Household Income: $80.6K", "US Mental Health Costs: $350B", "US Military Spending in 1939 (Constant 2024 Dollars): $29B", "US Military Spending at WW2 Peak (Constant 2024 Dollars): $1.42T", "US Military Spending in 1947 (Constant 2024 Dollars): $176B", "US Military Spending in 2024: $886B", "US Military Spending as Percentage of GDP: 3.5%", "US Population in 2024: 335 million people", "Senators for Treaty Ratification: 67 senators", "US Federal Campaign Spending (2024): $20B", "US Total Lobbying (2024): $4.4B", "Probability of Decisive Vote (US): 1.67e-08 probability", "Valley of Death Attrition Rate: 40%", "Value of Statistical Life: $10M", "Vitamin A Supplementation Cost per DALY: $37", "Estimated Annual Global Economic Benefit from Water Fluoridation Programs: $800M", "Return on Investment from Water Fluoridation Programs: 23:1", "Cost-Effectiveness Threshold ($50,000/QALY): $50K", "Percentage of Workforce Experiencing Productivity Loss from Chronic Illness: 28%", "Core Definitions", "ADAPTABLE Trial Patients Enrolled: 15.1 thousand patients", "Annual Working Hours: 2 thousand hours/year", "Approved Drug-Disease Pairings: 1.75 thousand pairings", "Average Life Extension per Beneficiary: 12 years", "Celebrity and Influencer Endorsements: $15M", "Community Organizing and Ambassador Program Budget: $30M", "Contingency Fund for Unexpected Costs: $50M", "Defense Industry Conversion Program: $50M", "Budget for Co-Opting Defense Industry Lobbyists: $50M", "Healthcare Industry Alignment and Partnerships: $35M", "Campaign Operational Infrastructure: $20M", "AI-Assisted Legal Work Budget: $50M", "Legal Defense Fund: $20M", "Legal Drafting and Compliance Work: $60M", "EU Lobbying Campaign Budget: $40M", "G20 Countries Lobbying Budget: $35M", "US Lobbying Campaign Budget: $50M", "Maximum Mass Media Campaign Budget: $1B", "Minimum Mass Media Campaign Budget: $500M", "Opposition Research and Rapid Response: $25M", "Phase 1 Campaign Budget: $200M", "Phase 2 Campaign Budget: $500M", "Pilot Program Testing in Small Countries: $30M", "Voting Platform and Technology Development: $35M", "Regulatory Compliance and Navigation: $20M", "Scaling Preparation and Blueprints: $30M", "Campaign Core Team Staff Budget: $40M", "Super PAC Campaign Expenditures: $30M", "Tech Industry Partnerships and Infrastructure: $25M", "Post-Victory Treaty Implementation Support: $40M", "Viral Marketing Content Creation Budget: $40M", "Annual Cost of Unpaid Caregiving: $6K", "Cell Therapy Approaches: 500 approaches", "Annual Encounter Rate: 0.5%", "Dismissal Rate: 90%", "Model Horizon: 10 years", "Initial Audience: 50 thousand people", "World Leader Count: 195 countries", "Childhood Vaccination Cost per DALY (Estimated): $30", "Concentrated Interest Sector Market Cap: $5T", "Cumulative Military Spending (All History): $180T", "Cumulative Military Spending (Fed Era): $170T", "Days Per Year: 365", "Mid-Range Funding for Commercial Dct Platform: $500M", "Percentage of Budget Defense Sector Keeps Under 1% treaty: 99%", "dFDA Annual Trial Funding: $21.8B", "Years to Reach Full Decentralized Framework for Drug Assessment Adoption: 5 years", "Decentralized Framework for Drug Assessment Core framework Annual OPEX: $18.9M", "Decentralized Framework for Drug Assessment Core framework Build Cost: $40M", "Stage 1 Observational Analysis Cost per Patient: $0.1", "Decentralized Framework for Drug Assessment Community Support Costs: $2M", "Decentralized Framework for Drug Assessment Infrastructure Costs: $8M", "Decentralized Framework for Drug Assessment Maintenance Costs: $15M", "Decentralized Framework for Drug Assessment Regulatory Coordination Costs: $5M", "Decentralized Framework for Drug Assessment Staff Costs: $10M", "Backup/Redundancy Cost per Patient (Monthly): $0.2", "Compute/API Cost per Patient (Monthly): $0.2", "Database Cost per Patient (Monthly): $0.3", "Raw Storage Cost per Patient (Monthly): $0.02", "Decentralized Framework for Drug Assessment Target Cost per Patient in USD: $1K", "Decentralized Framework for Drug Assessment One-Time Build Cost: $40M", "Decentralized Framework for Drug Assessment One-Time Build Cost (Maximum): $46M", "DIH Broader Initiatives Annual OPEX: $21.1M", "DIH Broader Initiatives Upfront Cost: $230M", "Percentage of Caregiving for Treatable Disease Conditions: 40%", "Epigenetic Drug Targets: 1.5 thousand targets", "Eventually Avoidable DALY Percentage: 92.6%", "Eventually Avoidable Death Percentage: 92.6%", "Minimum Investment for Family Offices: $5M", "Fundamentally Unavoidable Death Percentage: 7.37%", "Baseline Global GDP Growth Rate: 2.5%", "Global-to-US Political Cost Ratio: 5:1", "Hours Per Day: 24", "Hours Per Year: 8.76 thousand", "Human Protein-Coding Genes: 20 thousand genes", "IAB Mechanism Annual Cost (High Estimate): $750M", "IAB Political Incentive Funding Percentage: 10%", "Minimum Investment for Institutional Investors: $10M", "Average Commitment per Lead Principal: $350M", "Execution Rate Given Persuasion: 65%", "High-Alignment Lead Principals: 30 people", "Persuasion Rate Given Reach: 60%", "Reach Probability for High-Alignment Principals: 50%", "Launch Redundancy Factor: 1.25x", "Maximum Bond Investment for Lobbyist Incentives: $20M", "GDP Growth Boost at 30% Military Reallocation: 5.5%", "Minutes Per Hour: 60", "Money-Printer War Deaths: 97 million deaths", "Months Per Year: 12", "Standard Discount Rate for NPV Analysis: 3%", "Standard Time Horizon for NPV Analysis: 10 years", "Peace Dividend Conflict Elasticity: 1:1", "Direct Fiscal Savings from 1% Military Spending Reduction: $27.2B", "Pharma Phase 2/3 Cost Barrier Per Drug: $1.56B", "Pre-1962 Validation Years: 77 years", "QALYs per COVID Death Averted: 5 QALYs/death", "R&D Spillover Multiplier: 2x", "Safe Compounds Available for Testing: 9.5 thousand compounds", "Seconds Per Minute: 60", "Seconds Per Year: 31.5 million", "Sharing Time: 0.5 minutes", "Tested Drug-Disease Relationships: 32.5 thousand relationships", "Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance: $650M", "Reserve Fund / Contingency Buffer: $100M", "Treaty Campaign Duration: 4 years", "Viral Referendum Budget: $250M", "Infinite ROI from Redirected Spending: 0:1", "1% Reduction in Military Spending/War Costs from Treaty: 1%", "Trial-Relevant Diseases: 1 thousand diseases", "US Congress Members: 535 members", "US Dysfunction Premium vs Switzerland: 300%", "Overlap Discount Factor: 1:1", "Political Effort Multiplier (US): 0.7x", "US-Singapore Spending Gap: 2300%", "Switzerland-US Life Expectancy Gap: 6.5 years", "US-Switzerland Spending Gap: 300%", "Percentage of Captured Dividend Funding VICTORY Incentive Alignment Bonds: 10%", "Wishonia Path Probability (Year 20 EV Model): 90%", "US Base Political Spending: 28.8 billion" ], "published": true, "lastmod": "2026-03-10" } ], "pageCount": 2 } ] }